Podcasts about pharmaceutical research

Explore how AutoCruitment's technology-driven approach is transforming clinical trial recruitment, reducing enrollment timelines by 9 months while achieving a 97% increase in patient randomizations. Learn how their digital patient engagement strategy operates across 37 countries, addressing one of healthcare's most persistent challenges.Key Takeaways:Digital transformation in clinical trials achieving concrete ROI: 9-month reduction in enrollment timelinesGlobal scalability: Operating in 37 countries with 17 languagesProven track record: 120+ conditions and 97% increase in patient randomizationsDirect-to-patient digital engagement revolutionizing traditional recruitment methodsJill Pellegrino, CEO, AutoCruitmentMegan Antonelli, Chief Executive Officer, HealthIMPACT Live

Chris Micetich is a serial entrepreneur and investor who is a Founder of seven companies across three industries. Experienced Chief Executive Officer with a proven track record of success including closing the largest licensing deal in Canadian biotech history. Skilled in Pharmaceutical Research and Development (R&D), Biotechnology, Contract Research Organizations (CRO's) and Life Sciences. Extensive start-up experience. Remains actively involved in the innovation ecosystem mentoring visionary leaders. Graduate of the University of Alberta. Author of One Day You'll Understand: An Entrepreneur's Path To Purpose, Audience, And Voice Chris also sits on the Board of Explore Edmonton and is a mentor in CDL Rockies. Join Our Community of Canadian Entrepreneurs! Entrepreneurs are the driving force behind Canada's economy, and we're here to support them every step of the way. For exclusive insights, tips, and success stories from Canada's top business leaders, subscribe to our YouTube channel and follow us on Facebook, Instagram, LinkedIn, and Twitter. Want to stay ahead with the latest #entrepreneur podcasts, business strategies, and news? Don't miss out—subscribe to our bi-weekly newsletter for updates delivered straight to your inbox! Join thousands of Canadian entrepreneurs who rely on us for the resources they need to succeed.

Welcome to Episode 240 of Autism Parenting Secrets. This week, we're honored to welcome Dr. Theoharis Theoharides, a trailblazer in Autism and Mast Cell Regulation. With five degrees and decades of research, Dr. Theoharides offers powerful insights into the link between autism, allergies, eczema, and mast cells.In this episode, you'll learn: Breakthroughs in liposome technology for better supplement absorption.How to spot environmental triggers affecting your child.The role of luteolin in reducing neuroinflammation.Simple strategies for dietary changes and stress reduction.Dr. Theoharides emphasizes understanding autism's complexity, especially the roles of mast cells and neuroinflammation. Early identification, personalized treatments, and thoughtful supplementation can transform a child's well-being.Recorded at the Documenting Hope conference in Orlando, Florida, this discussion dives into actionable strategies and the potential to reverse autism symptoms.Dr. Theoharides's passion shines through, making this a must-listen.The secret this week is…Regulate Brain MAST CELLSYou'll Discover:The Extensive Track Record of Dr. Theoharides (3:19)What Exactly Are MAST Cells (7:14)Critical Concepts To Understand During Pregnancy (10:42)Why High MMP9 Is An Issue And What Helps To Reduce It (14:43)A Must-Do Regarding Supplements (27:14)A Simple Test To See If Mast Cells Are An Issue (28:45)MTHFR Considerations (33:23)Ways To Address Hyperactivity (36:28)About Our Guest:Dr. Theoharis Theoharides is Professor and Vice Chair of Clinical Immunology and Director of the Institute for Neuro-Immune Medicine-Clearwater, Nova Southeastern University, FL, and Adjunct Professor of Immunology at Tufts School of Medicine, where he was Professor and Director of Molecular Immunopharmacology & Drug Discovery, and Clinical Pharmacologist, Massachusetts Drug Formulary Commission (1983-2022). He served on the Board of the Institute of Pharmaceutical Research and Technology (IFET) and the Supreme Health Council of the Ministry of Health in Greece. He received his BA, MS, MPhil, PhD and MD degrees and the Winternitz Price in Pathology from Yale University. He also received a Certificate in Global Leadership from Tufts Fletcher School of Law and Diplomacy and a Fellowship at Harvard Kennedy School of Government. He trained in internal medicine at New England Medical Center, which awarded him the Oliver Smith Award, “recognizing excellence, compassion and service.” He received the Tufts Distinguished Faculty Recognition and Excellence in Teaching awards multiple times. He showed that the unique tissue immune cells, mast cells, communicate with the brain microglia and are critical for neuroinflammation. He has 493 publications (49,406 citations; h-index 113 placing him in the world's top 0.05% of most cited authors and the worldwide expert on mast cells by ScholarGPS and Expertscape. He was inducted into the Alpha Omega Alpha National Medical Honor Society, the Rare Diseases Hall of Fame, and the World Academy of Sciences. He developed novel dietary flavonoid supplements formulated in olive pomace oil to increase absorption. He has received 30 patents and trademarks.www.mastcellmaster.comwww.drtheoharides.comReferences in The Episode:www.algonot.comDocumenting Hope ConferenceAdditional Resources:Unlock the power of personalized 1-on-1 support, visit allinparentcoaching.com/intensiveTake The Quiz: What's YOUR Top Autism Parenting Blindspot?To learn more about Cass & Len, visit us at www.autismparentingsecrets.comBe sure to follow Cass & Len on InstagramIf you enjoyed this episode, share it with your friends.

What would you like to see more of? Let us know!In this episode of Discover Daily, we explore two major technological breakthroughs shaping our future. First, we discuss DeepMind's release of AlphaFold 3's source code, a significant advancement in protein structure prediction that promises to accelerate drug development by up to three years. With 76% accuracy in protein-ligand interactions and 65% accuracy in protein-DNA interactions, this open-source release marks a new era in computational biology and pharmaceutical research.We then delve into China's ambitious Solar Great Wall project, a massive renewable energy installation that stretches 400 kilometers across Inner Mongolia's desert landscape. This unprecedented initiative combines solar power generation with ecological restoration, featuring 196,000 solar panels in the Dalad Banner section alone. By 2030, the project aims to generate 180 billion kilowatt-hours annually, exceeding Beijing's current annual power consumption while simultaneously combating desertification.The dual-purpose design of the Solar Great Wall showcases how renewable energy projects can address multiple challenges simultaneously. Beyond power generation, the installation creates 50,000 new jobs, enables desert farming under the panels, and serves as a protective barrier for the Yellow River ecosystem. The project's innovative bifacial panels and AI-driven tracking systems demonstrate China's commitment to leading the global transition to sustainable energy.From Perplexity's Discover Feed:https://www.perplexity.ai/page/deepmind-releases-alphafold-co-jvNh2oy5TLyXE0SSrjYSCghttps://www.perplexity.ai/page/china-s-solar-great-wall-opa_xYm3RdO7j31AfESZuwPerplexity is the fastest and most powerful way to search the web. Perplexity crawls the web and curates the most relevant and up-to-date sources (from academic papers to Reddit threads) to create the perfect response to any question or topic you're interested in. Take the world's knowledge with you anywhere. Available on iOS and Android Join our growing Discord community for the latest updates and exclusive content. Follow us on: Instagram Threads X (Twitter) YouTube Linkedin

In this explainer episode, we've asked Callum Morris, Pharmaceutical Research and Development Insights Manager at Genomics England, to explain what happens in a clinical trial. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. If you've got any questions, or have any other topics you'd like us to explain, feel free to contact us on info@genomicsengland.co.uk. You can read the transcript below or download it here: https://www.genomicsengland.co.uk/assets/documents/Podcast-transcripts/What-happens-in-a-clinical-trial.docx Florence: What happens in a clinical trial? I'm joined with Callum Morris, Pharmaceutical Research and Development Insights Manager for Genomics England, to find out more. So, Callum, first things first. What is a clinical trial?   Callum: So, a clinical trial is a study that looks to people to answer a specific medical research question.  So, this involves gathering a group of participants that are willing to participate in providing evidence on how to improve clinical care. And so, the main purpose for a clinical trial is to evaluate health related outcomes between different groups of participants. If it's an interventional clinical trial, you change clinical care for one group and not another.  And evaluate whether the change you made improved health outcomes for that group, or if it's an observational clinical trial, you might focus on different groups but not change anything about their clinical care and collect real world data to understand how outcomes differ across the groups.  Florence: Can you briefly explain what we mean by real world data?   Callum: Sure. So real world data relates to data collected routinely as part of standard clinical care. So, it could be collected from your electronic health records, data from product or disease registries, or data gathered from other sources such as digital health technologies.  And all of this can inform on particular groups from the population you're interested in.  Florence: And are there different types of clinical trials?   Callum: Yes. Clinical trials can take many forms depending on the medical research question you're trying to answer. They could be related to understanding the risk of disease. So, evaluating a potential risk factor that you may be concerned with. They might evaluate preventing disease. So, what different approaches can you take to people who have never had the disease, and does this prevent its occurrence? You can have a clinical trial that looks at screening for disease. For cancer, that's really important.  Does a new screening approach mean more people with cancer can be identified earlier? And importantly, does this lead to an improvement in survival? You can have clinical trials that evaluate the different approaches to diagnosing a disease and can you diagnose a patient earlier and better?  And then the classical clinical trial is revolving therapeutics or different treatments, and you can have treatments that are addressing the disease itself. Or you'd have treatments that are controlling the symptoms of side effects you might get from another treatment you might be taking.   So even within a specific medical research question, you can have different clinical trials depending on how much evidence you already have regarding that question. For clinical trials involving the assessment of new treatments and therapies, these are broken down into three stages and we call these phases.  So, you have phase one, phase 2, and phase 3.  Florence: Can you explain a bit more about these phases?   Callum: Sure. So, the overarching medical research question might be, what is the safety profile of this new therapy, and does it work improving on the current standard of care? So, you'll break this down depending on the phase, and with each phase you expand your clinical trial to a larger population.  Phase ones are typically on a small group of people around, let's say 20 to 50, and are designed to check the safety of a new drug that's being entered into humans for the first time. Sometimes, especially in early phase cancer trials, you're trying to find the right dose for your patients.  So, you might take a small group, test them on a low dose, and if there are no severe reactions to the new drug, you start incrementally increasing your dose a little bit more. And this gives you a really good idea of the safety profile of your drug as you try it for the first time in a human population.  Next, you'll move on to a phase 2. And these are typically larger than your phase one, around 50 to 200 people. And, usually you use the dose recommended by the phase one. So instead of slowly adjusting your dose and just focusing on the drug safety profile, the phase 2 will evaluate the safety of the medicine in a large population, but also have an additional focus on health-related outcomes.  Is the medicine causing the effect you want? Whether that's relief of symptoms or for cancer reduction in the size of your cancer. If the data is really promising from your phase two, it will move to a phase 3. And the idea is the same, increasing the size of the population. typically phase threes can be from 300 to 3000 participants.  And the key thing here is that you will evaluate the potential benefit of your new treatment against the current standard of care. Normally, meaning the treatments that are already available in the clinic. Health regulators will need to look at all the data collected from all the trials before they approve it for the general population.  And typically, they need a phase 3 to do this. They need a phase 3 to confirm that the benefit provided by the treatment outweighs the potential risks associated with it, across a fairly large cohort of participants. And this is to ensure the therapy is appropriate to be given to the general patient population.  But also, a phase 3 is needed to see that if the new treatment is moving clinical care forward in the right direction and in providing improvements for patients against what is already available in the clinic. And this is the process by which we call it evidence-based changes, to make improvements to clinical care.  Florence: So then how do people join clinical trials?  Callum: So firstly, it's about becoming aware of the clinical trial. You might be referred to a clinical trial by your doctor who's been aware of it and where it is. Or you might be able to find a clinical trial using clinical trial databases or finding about them through patient advocacy groups.  And they should be able to tell you which hospitals are taking part in the clinical trial. So, the next step might be your doctor can contact someone on the research team, and there is always a principal investigator per research site that is always a medical professional.  The study team at the site have all undergone training from the people organising the trial to run through the protocols necessary to keep the trial consistent in different sites.  Once they've been contacted, you'll undergo a screening process, and what they'll determine is your eligibility for the trial. They might assess medical history or your health status. And if you're eligible for the trial, the next step is to provide informed consent. The healthcare team should provide detailed information about the trial, its risks and benefits, the aim of the trial, and who's funding it.  And what are the treatment options for participating and not participating in the trial? How long is the follow-up in the clinical trial? And what will happen if you leave the clinical trial? And then also what are the safety concerns for the clinical trials and the possible side effects if it's something to do with a new treatment. Once you've been informed of all these details and you agree to be part of the clinical trial, you'll sign a consent form, and that means you're officially enrolled in the clinical trial.  Florence: And what happens once someone is enrolled in a clinical trial?   Callum: Once you are in the trial, you'll follow the procedures outlined in the trial protocol. This can take many forms, but normally it involves more regular follow-ups and check-ins with the clinical care team. And this is to establish safety concerns and to enable lots of data collection.  There also may be additional checks related to health outcomes during the trial, and so the study team may want to take additional samples to understand what is happening physiologically during the study. There also may be additional questionnaires for you to fill out, to capture patient reported health outcomes.  And this is to understand the patient's quality of life whilst they're on the trial. So, depending on the protocol, you may be followed up for a set period of time, and that may get less frequent as time goes on. And of course, you may pull out of the trial at any point after which the follow up will stop.  So, following data collection, there may be a while before you see anything, but results should be published following analysis of the data.   Florence: And finally, why might someone want to be involved in a clinical trial?   Callum: Clinical trials are all about providing evidence to improve clinical care. At any time we want to make a change to healthcare, we want it to be evidence-based. And so, this requires lots of people all contributing in a group effort to generate a data set large enough to determine how to change our approach to healthcare and move the field forward for improving people's lives.  Florence: That was Callum Morris explaining what happens in a clinical trial. If you'd like to hear more explainer episodes like this, you can find them on our website www.genomicsengland.co.uk. Thank you for listening. 

Rare diseases present daunting challenges for researchers and clinicians. With limited data and resources available, developing effective treatments can feel like trying to solve a complex puzzle with missing pieces. However, Shweta Maniar, Director of Global Healthcare & Life Sciences Industry Strategy at Google Cloud, believes there is hope - and it comes in the form of Generative AI.  Listeners will come away with a deeper understanding of how this transformative technology can crack the code of rare diseases and unlock a future of better outcomes for patients in critical need. CopyHow this innovative technology can revolutionize rare disease researchThe unique capabilities of Generative AI models How they differ from traditional machine learning, enabling breakthroughs in areas like accelerating research, improving patient diagnosis, and streamlining treatment developmentReal-world case studies demonstrating the impact of Generative AIEthical considerations that must be navigatedShweta Maniar, Director of Global Healthcare & Life Sciences Industry Strategy, Google CloudMegan Antonelli, Chief Executive Officer, HealthIMPACT Live

Alex Schriver, Senior Vice President of Public Affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA), explains how he builds trust with key stakeholder audiences through internal and external localization efforts. He shares how he applies a campaign-style approach to communicate and engage with his team to “win the day.” Additionally, Alex emphasizes how leaders can ensure their employees' voices are genuinely heard and valued.

AZ Bio Week & Life Sciences Innovation w/ Joan Koerber-Walker - AZ TRT S05 EP36 (252) 9-16-2024   Things We Learned This Week AZ Bio mission to improve life and bioscience, & make AZ a Top Ten Bioscience state AZ Bio Week 2023 is Sep. 16, 5 Days Talks, Events & Awards 3 Ds - Discovery, Development, & Delivery - takes years, and $ billions to bring new drugs to market Their company members deal with diseases, medical devices & cancer research to cure it Combo of Gov't & Private Funding, University research & private company work     Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   LKIN: https://www.linkedin.com/in/joankoerberwalker  www.azbio.org Bio: As President and CEO of AZBio, Joan Koerber-Walker works on behalf of the Arizona Bioscience and Medical Technology Industry to support the growth of the industry, its members and our community on the local and national level. Ms. Koerber-Walker is also a life science investor and has served on the boards of numerous for-profit and non-profit organizations.       In the life science industry, Ms. Koerber-Walker serves as as Arizona's representative to the State Medical Technology Alliance (SMTA), a consortium of state and regional trade associations representing their local medical technology companies which she chaired in 2015 and  represents Arizona as a member of the Council of State Bioscience Associations (CSBA) and the Coalition of State Bioscience Institutes (CSBI). Active in the entrepreneurial and investment communities, she also serves as Chairman of the Board of the Opportunity Through Entrepreneurship Foundation which provides entrepreneurial education, mentoring and support to at-risk members of the community, on the Board of Advisors to CellTrust, Inc. which provides secure communication technology to the healthcare industry, and as Chairman of CorePurpose, Inc. which she founded in 2002. Ms. Koerber-Walker has been recognized as Executive of the Year by the Arizona Society of Association Executives, as a “Most Admired Leader” by the Phoenix Business Journal (2015),  in the pages of AZ Business Leaders (2013 thru 2020), Most Influential Women in Arizona Business (2014) and is a 2 time National Finalist for the Stevie Award which recognizes the work of women in business. Her past experience includes two years as the CEO of ASBA (the Arizona Small Business Association), service as a member of the Board of Trustees of the National Small Business Association in Washington D.C., President of the National Speakers Association/Arizona, Chair of the Board of Advisors to Parenting Arizona, the state's largest child abuse prevention organization, & much more.     AZBio:  Supporting Arizona's Life Science Industry for 19 Years (2003 – 2022) Learn more about Arizona's bioindustry: www.azbio.org | Facebook: AZBIO |Twitter: @AZBio @AZBioCEO We're part of a movement to create sustainable funding for life science innovation in Arizona. Learn more at www.AZAdvances.org  MOVING LIFE SCIENCE INNOVATIONS ALONG THE PATH FROM DISCOVERY TO DEVELOPMENT TO DELIVERY OUR VISION OF THE FUTURE: Arizona is a top-ten life science state. OUR MISSION: AZBio supports the needs of Arizona's growing life science ecosystem. The Arizona Bioindustry Association (AZBio) is a not-for-profit, 501(c)6 trade association supporting the growth of Arizona's life science sector. AZBio  Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector.  As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.   AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations. Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.   Arizona's bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona's universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.     Notes:   Seg 1   Biotech and life sciences industry in Arizona, has 3000 businesses and 36,000 employees. The economic impact in 2021 was $38.5 billion. AZ Bio would like to double, so by 2033, the impact would be $78 billion.   Examples of biotech companies in Arizona are Medtronic that makes medical devices, WL Gore, material sciences. Other companies in diagnostics, there are Sonoran Quest which does testing. This also Castle Bio Sciences, deals in cancer treatment. Some medicine companies are Bristol, Myers, and Calvari who deals in cancer drugs. Calvari is the bio science company of the year in 2024.   AZ Bio Science Week started in 2017. AZ Bio week starts September 16 and has events daily from Monday to Friday.   Seg 2   Neo clinical stage company dealing in heart health with aortic artery for the abdomen.   Another new company is prim dealing in MCT deficiency, compound growth and they are in clinical and testing stages.   Drugs get tested through computer models, and then on animals. Always have to worry about safety and ethics. FDA has very strict rules. You do not put people at risk, after monitor, during test and post monitoring. There's high-level quality control.     https://www.azbio.org/azbw2024   Events Summary: Monday - Women in Biotech Leading Women: Biotech & Beyond Join us for an evening of conversation and connections with our community's leading women as we kick off Arizona Bioscience Week in style!   Tuesday - Fundraising Fundraising Strategies for Life Science Startups  A compelling narrative is crucial when you are fundraising and communicating with life science investors.  This Life Science Nation (LSN) Global Fundraising Bootcamp covers topics related to executing a successful fundraise for your startup.      Wednesday – AZ Bio awards, philanthropy, entertainment, and AZ Advances The 20th Annual AZBio Awards & AZAdvances After Party Celebrate with the Educators, Researchers, and Organizations that are making life better for people in Arizona and around the world.  Join us at the Phoenix Convention Center as we honor the 2024 AZBio Award Winners. Hundreds of health innovators and business leaders will be celebrating at the 20th Annual AZBio Awards.   Thursday- White Hat Investor White Hat Life Science Investor Conference White Hat Investors 2024 showcases exciting biotech and medtech companies from across the Rocky Mountain & Southwest Region. Friday - Voice of the Patient, Bridge Cures Event Voice of the Patient Patients are the reason we do what we do.  Join the conversation on life science innovation from the patient perspective.  Ponte Cura: The Bridge to Cures Ponte Cura is a special donor appreciation event for the people and organizations supporting the Opportunity Through Entrepreneurship Foundation AZAdvances Initiative   AZ Advances: Arizonans are advancing life changing and life saving innovations along the path from discovery to development to delivery. AZAdvances is developing the funding that will help advance health innovations in Arizona today and for generations to come.  Charitable donations to the AZAdvances fund at the Opportunity Through Entrepreneurship Foundation, an Arizona based 501c3 public charity, are a way to support the creation of tomorrow's medical innovations.      Seg. 3   Replay Clips from: Preventing Cancer with a Vaccine w/ Stephen Johnston of Calviri   - AZ TRT S04 EP17 (179) 4-23-2023   Things We Learned This Week Calviri is working on a Vaccine to PREVENT Cancer, currently largest animal clinical trial Inflammation - starting points of bad cells Cancer - bad cells replicate Could Prevent other diseases & extend longevity of people's lives - ex.- help w/ dementia Tumors make bad proteins Calviri vaccine works on RNA (proteins) kills tumor, & arms immune system     Full Show: HERE         Best of Biotech from AZ Bio & Life Sciences to Jellatech: HERE   Biotech Shows: HERE   AZ Tech Council Shows:  https://brt-show.libsyn.com/size/5/?search=az+tech+council *Includes Best of AZ Tech Council show from 2/12/2023      ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the BRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ ‘Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.  

¿Quieres saber cómo acelerar tu metabolismo y quemar calorías sin esfuerzo? En este podcast, te presentamos 10 alimentos que te ayudarán a aumentar tu tasa metabólica y quemar más calorías incluso en reposo. Descubre cómo incorporar estos superalimentos en tu dieta diaria y disfruta de sus increíbles beneficios para la salud y la pérdida de peso.

The world of 340B has seen significant developments on the state and national levels in recent months. A second federal appeals court decision on 340B contract pharmacies came down in recent weeks, a new bill in Congress threatens to impose significant restrictions on hospital participation in 340B program, and more states move to protect covered entities from drugmaker restrictions. To understand these new developments, 340B Health President and CEO Maureen Testoni joins us to explain more. A second federal appeals court rules for drug companies In May, the D.C. Circuit Court of Appeals ruled that the 340B statute does not categorically prohibit drug manufacturers from imposing their own conditions on 340B. However, the court did note that manufacturers cannot impose a condition that effectively prevents a covered entity from purchasing a particular drug at the 340B price. This raises the importance of entities demonstrating situations in which they are cut off from all 340B access to a drug. Another appeals court based in Chicago has yet to issue a decision in its 340B contract pharmacy case. More states ban 340B restrictions as the industry increases state lobbying efforts  So far this year, Kansas, Maryland, Minnesota, Mississippi, and West Virginia have joined Arkansas and Louisiana in enacting laws to prohibit contract pharmacy restrictions on covered entities. But the pharmaceutical industry has become much more active in opposing ongoing legislative efforts in other states. A “dark money” group also has been running ads opposing these state bills by accusing covered entities of laundering taxpayer money to subsidize care for undocumented immigrants. New pharma-backed bill in Congress would slash 340B hospital eligibility U.S. House lawmakers recently introduced a bill known as the 340B ACCESS Act. The legislation is backed by the Pharmaceutical Research & Manufacturers of America (PhRMA) and the National Association of Community Health Centers (NACHC). It would impose significant restrictions on 340B hospital eligibility and access to savings, including by restricting 340B usage for insured patients and tying participation in the 340B program directly to levels of charity care. Resources: 1.      Statement on New Federal Legislation To Restrict 340B Hospital Eligibility2.      Statement on D.C. Circuit Appeals Court Decision on Drug Companies' 340B Restrictions3.      Report: 340B Hospitals Prescribe Medicare Part D Drugs to Greater Shares of Historically Underserved Patients4.      House Energy and Commerce Oversight and Investigations Subcommittee Hearing on 340B June 4

Listen Ad Free https://www.solgoodmedia.com - Listen to hundreds of audiobooks, thousands of short stories, and ambient sounds all ad free!

This Day in Legal History: First Union FormedOn May 1, 1794, a pivotal development in labor rights history occurred in Philadelphia with the formation of the Federal Society of Journeymen Cordwainers. This organization, consisting of skilled shoemakers, marks the establishment of the first trade union in the United States. The union was created as a response to the increasingly difficult economic conditions that tradesmen faced, including low wages and long working hours.The Cordwainers, recognizing the strength in numbers, aimed to leverage their collective bargaining power to negotiate better wages and working conditions. This was a significant step forward in the labor movement, as it introduced the concept of organized labor in America. The formation of this union was not just about improving pay; it was also about dignifying the labor force and providing workers a platform to voice their concerns.Philadelphia, being a hub of commerce and trade in the late 18th century, provided the perfect setting for such an organization. The city's workshops and bustling markets meant that there was a significant demand for skilled labor, which the Cordwainers could supply. However, with industrialization beginning to take root, these skilled workers found themselves under threat from cheaper, mass-produced goods.The Federal Society of Journeymen Cordwainers set a precedent that would be followed by other trades across the country. Their actions led to the establishment of similar societies and unions, which eventually contributed to the broader national labor movement. The Cordwainers themselves faced legal challenges, particularly in 1806, when they were involved in a landmark legal case concerning the rights of workers to organize, known as Commonwealth v. Pullis. In this case, the court ruled against the union, marking one of the first legal battles over the legitimacy of trade union activities in the United States.Despite the legal setbacks, the resilience and pioneering spirit of the Federal Society of Journeymen Cordwainers inspired subsequent generations of workers to fight for their rights. Their legacy is a testament to the enduring struggle for fair labor practices and workers' rights. This day in legal history not only marks the formation of America's first trade union but also celebrates the long journey towards justice and equity in the workplace.The US Patent and Trademark Office (PTO) recently proposed a rule that would require pharmaceutical companies to submit unredacted settlement agreements involving patent challenges to a new repository. This rule is aimed to assist the Federal Trade Commission (FTC) and the Department of Justice (DOJ) in detecting antitrust violations. The proposal arose from concerns that these settlements, often reached in administrative tribunals like the Patent Trial and Appeal Board (PTAB), could be used to delay cheaper biosimilar drugs from entering the market.Evan Diamond, special counsel, noted that the PTO has not clearly defined "good cause" for accessing these agreements, which might increase third-party access and create confidentiality concerns. The fear is that the database could enable federal agencies to easily assess the frequency of potentially anticompetitive pay-for-delay settlements—a practice scrutinized under the Supreme Court's 2013 decision in FTC v. Actavis, which ruled such deals could be illegal.The proposal aligns with an executive order from President Joe Biden encouraging interagency cooperation to prevent practices that unjustifiably delay generic and biosimilar competition. This move has heightened the pharmaceutical industry's fears of increased antitrust enforcement, particularly as the FTC has been actively challenging questionable patent listings that could hinder the approval of generic drugs.Agencies like the FTC and DOJ already have certain reporting requirements under the Medicare Modernization Act for pharmaceutical companies, but the PTO's rule could capture additional agreements that do not meet existing criteria. This has sparked debate over the necessity and potential overlap of the new rule.The pharmaceutical industry, represented by major lobbyist groups like Pharmaceutical Research and Manufacturers of America and the Biotechnology Innovation Organization, has expressed strong opposition, citing concerns over the scope of PTO's authority and the ambiguity around the "good cause" criterion.This development highlights a broader regulatory push against anti-competitive practices not only in pharmaceuticals but also in other sectors like technology, where companies like Apple and Google are frequently involved in patent litigation.In summary, the PTO's proposed rule could significantly impact how pharmaceutical settlements are handled, potentially exposing companies to greater antitrust scrutiny. This measure reflects a governmental shift towards stricter oversight of patent practices to foster competition and reduce drug prices.Drug Makers Exposed to Antitrust Probes if Patent Cache AdoptedThis term, Jones Day had the highest number of attorneys—five in total—arguing cases at the U.S. Supreme Court, more than any other firm. Among them, John Gore and C. Kevin Marshall presented for the first time at the high court. Other experienced attorneys like former U.S. Solicitor General Noel Francisco, and partners Hashim Mooppan and Traci Lovitt also argued cases, contributing to the firm's visibility.In comparison, other leading law firms such as Gibson Dunn, Hogan Lovells, and Williams & Connolly had slightly fewer representatives. Gibson Dunn introduced three new attorneys to the Supreme Court lectern, including Theane Evangelis, D. Nick Harper, and Eugene Scalia, who is a son of the late Justice Antonin Scalia. Hogan Lovells' Jessica Ellsworth argued for the first time, including in a significant case regarding the abortion drug mifepristone. Williams & Connolly had Lisa Blatt argue all four of their cases, marking her 50th Supreme Court appearance.Overall, the season saw a mix of seasoned veterans and newcomers. Of the total 152 arguments made, over half were by attorneys who had appeared at least five times before, while a quarter were by first-time arguers. This highlights both the depth of experience and the ongoing introduction of new talent in the legal field's highest echelons.Jones Day Leads in Supreme Court Arguments With New FacesJohnson & Johnson (J&J) is currently seeking approval for an $11 billion settlement to resolve ongoing litigation concerning its talc-based baby powder, which has been alleged to cause ovarian cancer. This amount is a significant increase from a previous offer of $8.9 billion. J&J's strategy involves a third attempt at a bankruptcy filing, specifically a pre-packaged bankruptcy, which allows for faster processing if they secure enough creditor support—in this case, needing the approval of 75% of the talc plaintiffs.The company proposes to pay $6.48 billion over 25 years to settle ovarian cancer claims, but it has not specified how funds will be divided between existing and future claims. Additionally, J&J has nearly settled all claims regarding mesothelioma believed to be caused by asbestos in the powder. This settlement approach follows multiple failed attempts to use Chapter 11 to manage these lawsuits, which now number almost 60,000.These lawsuits have been a significant factor depressing J&J's stock price, according to analysts. Despite the legal challenges, J&J maintains that its talc products do not cause cancer and asserts that it has marketed its baby powder responsibly for over a century. A recent verdict, however, led to a $45 million payout to a family, implicating J&J and its spinoff Kenvue in the ongoing litigation.The company's persistence in seeking a bankruptcy-based settlement reflects its strategic approach to managing a complex legal challenge that impacts thousands of plaintiffs and could potentially set a precedent in how large corporations handle mass tort liabilities through bankruptcy court.J&J Seeks Backing for $11 Billion Baby Powder Cancer SettlementIn President Joe Biden's Fiscal Year 2025 Budget Proposal, a notable change is the suggestion to tax unrealized gains—value increases in assets not yet converted into cash through a sale. This marks a significant shift from traditional tax frameworks, which typically avoid taxing unrealized gains due to their complexity, potential liquidity issues, and difficulties in implementation.The rationale behind this proposal is to ensure tax fairness by capturing increases in wealth that currently escape taxation. For example, if a billionaire's stock appreciates significantly without being sold, they realize no taxable gain. However, if they borrow against these increased values, they effectively use this appreciation as a means to generate wealth without incurring tax liabilities. This situation presents a loophole where wealth can grow and be leveraged without contributing to the tax base.The FY2025 budget aims to address these disparities by proposing a tax on unrealized gains for very high-net-worth individuals and entities that have not been subject to a tax event in the last 90 years. This approach seeks to broaden the tax base without raising rates, aiming to increase tax revenue from the wealthy without additional burdens on middle and lower-income individuals.This policy shift acknowledges the need to adapt tax strategies to a changing economic environment where traditional taxation methods no longer capture all forms of wealth accumulation. The proposal suggests that a more equitable tax system requires taxing wealth as it grows, even if it is not realized through a sale. By proposing to tax unrealized gains, the administration intends to correct imbalances allowing substantial wealth to accumulate tax-free, signaling a significant potential change in how wealth is taxed in the U.S.Unrealized Gain Tax—A Coming Sea Change in FY2025 Budget Proposal? Get full access to Minimum Competence - Daily Legal News Podcast at www.minimumcomp.com/subscribe

In November 2021, Arkansas enacted a law, known as Act 1103, that prohibited drugmakers from placing restrictions on 340B contract pharmacies and child sites. The Pharmaceutical Research and Manufacturers of America (PhRMA) immediately filed suit to block implementation of Act 1103, delaying enforcement of the law for nearly 2 years. However, on March 12, 2024, the U.S. Court of Appeals for the Eighth Circuit rejected PhRMA's arguments and ruled Act 1103 is valid and enforceable. In the podcast, we talk about the implications of the ruling for the broader 340B program and covered entities nationwide.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

The pharmaceutical industry in China is undergoing a significant transformation with the adoption of artificial intelligence (AI) technology. A recent study published in the Future Journal of Pharmaceutical Sciences evaluates… Source

Can the gatekeepers of capital truly predict the next groundbreaking innovation, or does overregulation stifle potential? This question sits at the heart of today's pressing conversation with Commissioner Uyeda on The Angel Next Door Podcast with host Marcia Dawood. Entrepreneurs and innovators face a myriad of challenges, but how can regulation strike the right balance between protection and empowerment? This episode dives into the complexities of capital formation, regulatory insight, and the budding entrepreneur's right to risk.Commissioner Uyeda, currently serving his second term at the Securities and Exchange Commission (SEC), brings a wealth of knowledge to the table. Sworn in December 2023 for another five-year term, the commissioner is poised to witness significant rule adoptions and finalizations, especially under Chair Gensler's directive leadership. Appointed as one of five bipartisan SEC commissioners, Uyeda is instrumental in ensuring the regulatory body remains effective and cost-efficient amid a rapidly evolving electronic era.This episode is a must-listen for anyone involved or interested in the startup ecosystem, angel investing, and the broader financial landscape of entrepreneurial ventures. Marcia and Commissioner Uyeda touch on pivotal issues, from the nonpartisanship needed within the SEC to the nuanced differences between fraud and investment losses, as well as the practical concerns of raising the financial thresholds for accredited investors. With an eye towards inclusive innovation and insights that could shape the future of investment policies, The Angel Next Door Podcast shines a spotlight on the delicate interplay between regulatory frameworks and the inherent risk-taking that fuels American ingenuity. To get the latest from Commissioner Uyeda, you can follow him below!LinkedIn - https://www.linkedin.com/in/mark-uyeda-5227aa5/https://www.sec.gov/news/speech/uyeda-remarks-securities-regulation-institute-012224https://www.sec.gov/about/commissioners/mark-t-uyeda Sign up for Marcia's newsletter to receive tips and the latest on Angel Investing!Website: www.marciadawood.com And don't forget to follow us wherever you are!Apple Podcasts: https://pod.link/1586445642.appleSpotify: https://pod.link/1586445642.spotifyLinkedIn: https://www.linkedin.com/company/angel-next-door-podcast/Instagram: https://www.instagram.com/theangelnextdoorpodcast/TikTok: https://www.tiktok.com/@marciadawood

On today's podcast, host Jonah Comstock welcomes Christina Corridon, global lead of oncology at ZS Associates and Sandeep Sangwan, who leads the knowledge services R&D team at ZS. They discuss how research conducted in space can advance life sciences research, especially in oncology.  

https://www.solgood.org - Check out our Streaming Service for our full collection of audiobooks, podcasts, short stories, & 10 hour sounds for sleep and relaxation at our website

In this session, hear from various experts about what it takes to get a drug to market. The bottom line is that research simply does NOT equal a cure. Learn from some of the best in the uveal melanoma pharma world about the process of bringing a treatment or new drug to market. Experts include Dr. Katz, Chief Medical Officer at TriSalus Life Sciences; Dr. Wade from Aura Bioscienes, Lucinda Innes, a PHD research student investigating uveal melanoma, and research board member Kevin. Dr. Steven Katz has been the Chief Medical Officer at TriSalus since September 2020 and is Chairman of the Scientific Advisory Board, which includes leadership of TriSalus' Translational Immunotherapy Laboratory. Christian Wade, PhD is a medical affairs leader with over 16 years of experience in the pharmaceutical industry. He is currently the Director of Field Medical Affairs at Aura Biosciences, where he is responsible for leading the field medical affairs team for a portfolio of innovative therapies. Dr. Wade is a graduate of the University of San Francisco and holds a PhD in pharmacology from the University of Washington. He is a member of the Medical Affairs Association and the Pharmaceutical Research and Manufacturers of America. Lucy was born and raised in Seattle and attended Western Washington University, where she earned her degree in biochemistry. In 2021, she pursued her PhD at Weill Cornell Medicine in New York City. During her first year there, she was diagnosed with Ocular Melanoma. This personal challenge inspired her to redirect her research focus towards the disease. Since her diagnosis in the fall of 2022, Lucy has been delving into the interactions between the immune system and ocular melanoma, aiming to improve the future of immunotherapies. Email questions to contact@acureinsight.org ANNOUNCEMENTS: 5K SITES ARE OPEN FOR REGISTRATION NEAR YOU! Start your team and bring your community to get involved!  November 11, Los Angeles CA https://runsignup.com/Race/CA/SantaMonica/LookinForACureLosAngeles November 19, Phoenix, AZ https://runsignup.com/Race/AZ/Scottsdale/LookinforaCure5k December 9, Dallas FTW TX https://runsignup.com/Race/TX/FortWorth/LookinForACureFortWorth December 10, Houston, TX https://runsignup.com/Race/TX/Houston/LookinForACureHouston January 20, 2024 Orlando FL https://runsignup.com/Race/FL/Orlando/LookinForACureTampa January 21, 2024, Miami FL https://runsignup.com/Race/FL/Miami/LookinForACureMiami Head to our site to register for a 5K Lookin' for a Cure near you for the remainder of the year!! www.lookinforacure.org Subscribe to the newsletter to stay in the know Newsletter link Email contact@acureinsight.org for questions regarding any upcoming events! ********* Be sure to follow us on Facebook, Twitter, Linked In, or  Instagram @acureinsight, for more stories, tips, research news, and ideas to help you navigate this journey with OM! *A Cure in Sight is a 501c3 organization. All donations made can help fund our podcast to educate patients, fund research, aid patients, and more! Donate $10 $15 $20 today to help A Cure in Sight in their quest to find a cure. Contribute via  PAYPAL OR VENMO or reach out directly to contact@acureinsight.org 

Recorded at NC Life Sciences Organization's 2023 annual meeting, hosts Heather and Matthew welcome Christine Harhaj, the Senior Director for Pharmaceutical Research and Manufacturers of America (PhRMA). They have an insightful conversation about the pharmaceutical industry and advocating for policies that enable a patient-centered ecosystem. Listen to episode 168 now!

In this bitesize feature, Amgen's CEO explains why Iceland's isolated population make it a useful sample for understanding how disease arises from a genetic standpoint, and what this means for the drug discovery pipeline.  In the full interview Bob discusses timelines and priorities, the use of AI in accelerating drug development, biologics, facing setbacks on the road to approvals, and the challenge of running a company which has a presence in over 100 countries. Listen or watch here. Money Maze Vignettes are short extracts taken from some of our most popular episodes, which we found interesting or struck a chord with our listener community.  The Money Maze Podcast is kindly sponsored by Schroders,  Bremont Watches, and LiveTrade. 

Just over a month ago we lost Bob Barker, the man who taught us all about the brutal nature of capitalism one pricing game at a time. Now, thanks to the Inflation Reduction Act, the federal government is going to be playing a role in determining the prices for some of our favorite products. No, we're not talking about cars or family vacations to the Bahamas – we're talking about the prescription drugs that keep us alive! As the Biden Administration enters its own Showcase Showdown with Big Pharma, we're taking a full episode to break down what that means and whether the result will be prices we can actually afford. https://www.youtube.com/watch?v=cnxbIhEPhs0&t=1s Show Notes Our first (and only) contestant is Alex Lawson! He is the Executive Director of Social Security Works, the convening member of the Strengthen Social Security Coalition— a coalition made up of over 340 national and state organizations representing over 50 million Americans. Alex's organization played a critical role in moving the Democratic Party (mostly!) away from efforts to cut Social Security, and has been shifting the momentum towards expanding Social Security. Social Security Works is also a key ally of ours in the national fight for Medicare for All! Alex, come on down! Alex starts by telling us about the time he took a camera to PhRMA's (the Pharmaceutical Research and Manufacturers of America) office the day of the Inflation Reduction Act signing ceremony. He conducted person-on-the-street interviews, asking if they knew PhRMA spent hundreds of millions of dollars to keep Medicare from being able to negotiate drug prices, and if they had any messages for the folks in the building? Most of the responses were of the "f-you PhRMA, we got you!" variety. PhRMA has literally never lost until the Inflation Reduction Act was passed. Even though it's modest, Medicare went from having no authority over drug prices to the authority and mandate to find the fairest price for certain drugs is a huge loss to the industry. Alex wants listeners to understand that this win is as simple as it sounds. Who buys the most drugs in the world? Medicare. Why doesn't Medicare tell the pharmaceutical companies what they're willing to pay? This is called the Maximum Fair Price. No other peer nation doesn't have some kind of negotiated standard for drug prices. While our guest and hosts would prefer that Medicare be allowed to negotiate the prices of all drugs used by beneficiaries, PhRMA was successful in limiting the Inflation Reduction Act drug provisions to only apply to ten pharmaceuticals. (Still, pharmaceutical companies are suing to block the implementation of price negotiations.) Negotiating the prices for only ten drugs may seem like a drop in the bucket, but the cost of those ten drugs alone make up a huge amount of Medicare's spending on Medicare Part D. And in coming years Medicare will be able to negotiate over ten more drugs, and so on. This will squish the most excessive profiteering of the pharmaceutical industry and deliver savings of $9 or $10 billion dollars a year. We give President Biden credit for taking an aggressive stance against PhRMA to finally make good on an evergreen Democratic campaign promise to lower drug prices. But we also give ourselves some credit. First there was the debate in Congress in 2019 over HR3, the Lower Drug Costs Now Act. Advocacy by groups likes ours resulted in the House passing a robust bill that would have dramatically lowered drug costs. Then in 2021 both Healthcare-NOW and Social Security Works fought hard to win major expansions of Medicare in the Build Back Better bill (we were on track to win a lot more than prices for ten drugs). But Senators Joe Manchin and Kyrsten Sinema tanked the whole bill in the Senate. Those two battles led us to the Inflation Reduction Act aiming high from the start, and resulting in a bill that will make a big impact on drug spending by Medicare.

  AZ Bio Week & Life Sciences Innovation w/ Joan Koerber-Walker - AZ TRT S04 EP37 (200) 9-17-2023   Things We Learned This Week AZ Bio mission to improve life and bioscience, & make AZ a Top Ten Bioscience state AZ Bio Week 2023 is Sep. 25 – 29 – 5 Days Talks, Events and Awards 3 Ds - Discovery, Development, & Delivery - takes years, and $ billions to bring new drugs to market Their company members deal with diseases, medical devices & cancer research to cure it Combo of Gov't & Private Funding, University research & private company work       Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   LKIN: https://www.linkedin.com/in/joankoerberwalker  www.azbio.org Bio: As President and CEO of AZBio, Joan Koerber-Walker works on behalf of the Arizona Bioscience and Medical Technology Industry to support the growth of the industry, its members and our community on the local and national level. Ms. Koerber-Walker is also a life science investor and has served on the boards of numerous for-profit and non-profit organizations. In the life science industry, Ms. Koerber-Walker serves as as Arizona's representative to the State Medical Technology Alliance (SMTA), a consortium of state and regional trade associations representing their local medical technology companies which she chaired in 2015 and  represents Arizona as a member of the Council of State Bioscience Associations (CSBA) and the Coalition of State Bioscience Institutes (CSBI). Active in the entrepreneurial and investment communities, she also serves as Chairman of the Board of the Opportunity Through Entrepreneurship Foundation which provides entrepreneurial education, mentoring and support to at-risk members of the community, on the Board of Advisors to CellTrust, Inc. which provides secure communication technology to the healthcare industry, and as Chairman of CorePurpose, Inc. which she founded in 2002. Ms. Koerber-Walker has been recognized as Executive of the Year by the Arizona Society of Association Executives, as a “Most Admired Leader” by the Phoenix Business Journal (2015),  in the pages of AZ Business Leaders (2013 thru 2020), Most Influential Women in Arizona Business (2014) and is a 2 time National Finalist for the Stevie Award which recognizes the work of women in business. Her past experience includes two years as the CEO of ASBA (the Arizona Small Business Association), service as a member of the Board of Trustees of the National Small Business Association in Washington D.C., President of the National Speakers Association/Arizona, Chair of the Board of Advisors to Parenting Arizona, the state's largest child abuse prevention organization, & much more.     AZBio:  Supporting Arizona's Life Science Industry for 19 Years (2003 – 2022) Learn more about Arizona's bioindustry: www.azbio.org | Facebook: AZBIO |Twitter: @AZBio @AZBioCEO We're part of a movement to create sustainable funding for life science innovation in Arizona. Learn more at www.AZAdvances.org  MOVING LIFE SCIENCE INNOVATIONS ALONG THE PATH FROM DISCOVERY TO DEVELOPMENT TO DELIVERY OUR VISION OF THE FUTURE: Arizona is a top-ten life science state. OUR MISSION: AZBio supports the needs of Arizona's growing life science ecosystem. The Arizona Bioindustry Association (AZBio) is a not-for-profit, 501(c)6 trade association supporting the growth of Arizona's life science sector. AZBio  Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector.  As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.   AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations. Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.   Arizona's bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona's universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.         Notes:     Seg 1   BRT is now AZ Tech Roundtable 2.0   Talking AZ tech scene from AZ Tech Council to AZ Bio to Venture Café   Resources and tips to find networking and funding info   Thank you to the tech community for the support and great guests           Seg 2 – 4   Joan joins BRT to talk about AZ Bio, and their mission to improve life and bio science -organization deals in medical devices, diseases, cancer research. Companies join AZ bio as members, 275+ in Arizona.   What is the ROI in Arizona - $25 bill invested. ROI has been $38 billion in 2021 in economic impact.   AZ ranks about 30th. To get in the top 10 needs to be about $78 billion of economic impact per year. Looking to double the impact ($60 billion) by 2030.   3 D's – Discovery. Development, Delivery     AZ Bio Week – 20 Years of Impact - Sep. 25 – 29, 2023 https://www.azbio.org/azbw2022   Presented by AZBio and the Arizona Commerce Authority   Here are some of the Events & Talks:   Mon. Sep. 26 Critical Path to Women Leading in Science Please join C-Path for a 90-minute roundtable discussing the Critical Path Institute's programs and consortia, highlighted by various women leaders at this public-private partnership. The team will discuss how C-Path contributes to transforming and accelerating the medical product development process, as well as their personal professional development journey. The roundtable will include an interactive Q&A session, where the audience can ask specific questions about C-Path activities and, more generally, scientific career paths.  Leading Women: Biotech & Beyond Join us at Perkins Coie for an evening of conversation and connections with our community's leading women as we kick off Arizona Bioscience Week in style!   Tues. Sep. 27 Discovering and Developing New Medicines in Arizona The 4th Annual Drug Discoveries and Development Summit will highlight key areas of research in discovering effective drug candidates in diseases such as cancer, COVID 19, aging, nanotechnology, and other prevalent diseases in Arizona while establishing collaborations that enable success in these key areas.   Presented by the University of Arizona R. Ken Coit College of Pharmacy Arizona Center for Drug Discovery and the University of Arizona Cancer Center.     Wed. Sep. 27 AZAdvances Life Science Innovation Fast Pitch Join us at the Phoenix Convention Center for Fast Pitch presentations featuring Arizona life science innovators then join us for the  the AZBio Awards. (AZBio Awards or White Hat registration required.) The 18th Annual AZBio Awards & Life Science Fiesta Celebrate with the Educators, Researchers, and Organizations that are making life better for people in Arizona and around the world.  Join us at the Phoenix Convention Center as we honor the 2022 AZBio Award Winners and come together to be inspired and reconnect.   Thu. Sep. 28 White Hat Life Science Investor Conference Join us at the Phoenix Convention Center for White Hat 2022.  Accredited investors and investment funds will have the opportunity to hear from and connect with some of the most exciting Life Science Companies from across the Rocky Mountain Southwest Region.  Since its launch in 2014, Companies presenting at White Hat Have gone on to raise $1.6 billion in investments. Note:  White Hat Registration Includes the AZBio Awards and Life Science Fiesta on Wednesday evening.   Fri. Sep. 29 Voice of the Patient Patients are the reason we do what we do.  Join the conversation on life science innovation from the patient perspective.  This event will be held at the new Creighton University Health Sciences Campus in Phoenix.   Career Panel: Q&A in Nanotechnology, Synthetic Biotechnology, and Medical Fields Synthetic Biotechnology, Nanotechnology? Doesn't that only exist in Sci-Fi or superhero movies? The short answer is NO! Curious about the journey of what it takes to become a registered nurse or physical therapist in-home care? Your students will surely be at the edge of their seats listening to this panel of professionals. Please join us as Dr. Mario Blanco, President, and CEO of Nanopec, Dr. Rebecca Cook, Research Scientist for INanoBio, Bridget Gessel, Registered Nurse and Case Manager at the Mayo Clinic and Asya Rudikoff, Physical Therapist and Director of Strategy and Innovation for Team Select Home Care, share about their respective fields and career journey.   Ponte Cura: The Bridge to Cures Ponte Cura is an inspirational celebration under the stars supporting the Opportunity Through Entrepreneurship Foundation AZAdvances initiative mission to advance health innovation in Arizona.  The Ponte Cura experience includes a cocktail reception, open air concert, and after party.  This event is by-invitation only and in appreciation of the donors and volunteers supporting the AZAdvances Initiative.          Best of Biotech from AZ Bio & Life Sciences to Jellatech: HERE   Biotech Shows: HERE   AZ Tech Council Shows:  https://brt-show.libsyn.com/size/5/?search=az+tech+council *Includes Best of AZ Tech Council show from 2/12/2023      ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the BRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ ‘Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.

To kick off South Asian Trailblazers Season 7, power duo Dr. Vas Narasimhan (CEO of Novartis) and Dr. Srishti Gupta Narasimhan (Physician Leader in Health & Education) join Simi all the way from Basel, Switzerland for a LIVE recording at Novartis Headquarters in Cambridge, MA. WATCH this episode on YouTube.South Asian Trailblazers is dedicated to elevating leading South Asians. To learn about our events, subscribe to our newsletter at SouthAsianTrailblazers.com and follow us on Instagram, LinkedIn, Facebook, and YouTube.Vas Narasimhan and Srishti Gupta Narasimhan are two highly accomplished individuals...who also happen to be married. In this conversation, Simi delves into how Vas and Srishti first met at Harvard Medical School, Srishti's two decades at McKinsey and board service in biotech, and Vas' varied leadership roles at Novartis leading up to the moment he was named CEO of the world-renowned pharma company. It's an extraordinary journey that encompasses multiple moves across the world — with Srishti and Vas rising in their respective careers, while also supporting each other's unique aspirations and building a family. It's one of our most special episodes yet.  About Srishti: Dr. Srishti Gupta Narasimhan is a physician leader who dedicates her time to board service at Idorsia Pharmaceuticals, the Norrsken Foundation, and the BackPack Foundation. Previously, Dr. Gupta spent 2 decades at McKinsey as a Senior Expert in the Global Health Practice. She also supported talent programs as Global Director for McKinsey Alumni & Strategy, Director of Global Programs, and Director of Diversity and Inclusion. She holds a BA, MA, MPP, and MD from Harvard University and an M. Phil from the University of Cambridge. About Vas: Dr. Vasant Narasimhan is the CEO of Novartis. Since becoming CEO in 2018, Vas has led a transformation to build a fully focused medicines company. He leads 105,000 associates across 140 countries. Since joining Novartis in 2005, Vas has held myriad roles, including Global Head of Development for Novartis Vaccines, Global Head of Drug Development, and Chief Medical Officer. He is an elected member of the National Academy of Medicine and Chair of the Pharmaceutical Research and Manufacturers of America. He holds a BS from the University of Chicago and an MD/MPP from Harvard University.Visit Scrumptious Wicks & Prana Kitchens.For more episodes, visit us at southasiantrailblazers.com. Subscribe to our newsletter to get new episodes and updates on our latest events in your inbox. Follow us @southasiantrailblazers on Instagram, LinkedIn, Facebook, and Youtube.

In this podcast, Scott Summerfield, Senior Director, Pharmaceutical Metabolism at Pharmaron discusses his recent publication on Free Drug Theory (FDT) with Simon including the principles, arguments, and project impact. This article was an invited contribution to a special edition of the Pharmaceutical Research Journal recognizing the achievements of Professor Margareta Hammarlund-Udenaes and Kp,uu.The episode addresses the following questions:What is the FDT?How FDT relates to fundamental physical and biochemical principles?How ambiguity in its definition can hamper discussions in drug design?Importance of linking drug-at-target concentrations to drug-target bindingHow to apply FDT as a starting point to understanding concentration-effect relationships and PK/PD?Speaker:Scott Summerfield, Ph.D.  - Senior Director, Pharmaceutical Metabolism at PharmaronDr Scott Summerfield is currently Senior Director and Head of Pharmaceutical Metabolism at Pharmaron where he leads the UK group and its support of the Life Sciences industry.  He studied Chemistry at Coventry University followed by a PhD in Biological Mass Spectrometry at Warwick University and then a Post Doctoral fellowship at Manchester University.  Scott joined the Pharma industry in 1997 as a member of SmithKline Beecham's DMPK group.  At the formation of GSK he moved to Neuroscience Discovery serving in a range of roles from leading the bioanalytical and biotransformation team, DMPK program representative, and member of the company's Blood-Brain Barrier Working Group.  Scott has led WW groups supporting nonclinical and clinical PK and Biomarker Bioanalysis and has published over 60 scientific articles and book chapters.  He is a Fellow of the Royal Society of Chemistry, a children's book author, a professional Coach, and a Kung Fu instructor.  Reference:Summerfield, S.G., Yates, J.W. and Fairman, D.A., 2022. Free Drug Theory–No Longer Just a Hypothesis?. Pharmaceutical Research, 39(2): 213-222. Stay tuned for more podcasts in our Pharmaron DMPK Insights Series!

In this podcast, Dr. Paul Morgan, Head of DMPK at Grünenthal Group, discusses the development of the publication that introduced the “5R framework” and improved the likelihood of AstraZeneca candidate survival from candidate drug nomination to Phase III. We will then discuss how the area has developed since then and where the field may go in the future.The episode addresses the following questions:What was the situation like that led to the development of the 5Rs?How was the analysis conducted?How was this analysis accepted both within the organization and externally?What changes occurred as a result of this?As we sit here today has this work led to the improvements suggested?What do you see as the future? Have we done enough? What else is needed?Speaker:Paul Morgan, Ph.D. - Head of DMPK at Grünenthal GroupDr Paul Morgan has worked in Pharma R&D for 30 years across multiple therapeutic areas taking projects from early discovery through all stages of drug development and registration.  With specialism in Drug Metabolism and Pharmacokinetics (DMPK), he has led R&D departments in Pfizer, AstraZeneca, Sosei Heptares and now Grunenthal working across the interface between DMPK and Med Chem, Pharmacology, Safety, Clinical and CMC.  He has a keen interest in R&D productivity enhancement and has contributed to major initiatives at both Pfizer and AstraZeneca to introduce frameworks for the improvement of drug survival.   Paul is an honorary senior lecturer in Department of Pharmacology at University of Liverpool where he did his PhD.   Paul is originally from Belfast, Northern Ireland and is currently based in North-West England just outside Manchester.  He is married with two grown-up children and a lively dog!References:Morgan, P., et al, 2018. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nature reviews Drug discovery 17.3: 167-181.Summerfield, S.G., Yates, J.W. and Fairman, D.A., 2022. Free Drug Theory–No Longer Just a Hypothesis?. Pharmaceutical Research, 39(2): 213-222. Smith, D.A., and Rowland, M., 2019. Intracellular and intraorgan concentrations of small molecule drugs: theory, uncertainties in infectious diseases and oncology, and promise. Drug Metabolism and Disposition 47.6: 665-672.Smith, D.A., Di, L. and Kerns, E.H., 2010. "The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery." Nature reviews Drug discovery, 9.12: 929-939.Stay tuned for more podcasts in our Pharmaron DMPK Insights Series!

Find links to all the following stories as well as other law and legal-adjacent stories at esq.social Links. On this day in history August 29, 1957, the Civil Rights Act of 1957 was passed by congress – the first piece of federal legislation aimed at civil rights since reconstruction.Prompted by the Supreme Court's landmark 1954 ruling in Brown v. Board of Education, which ignited public debate on school desegregation, the act aimed to address the widespread disenfranchisement of African Americans in the Southern United States. President Dwight D. Eisenhower initially proposed the bill to bolster federal protection for African American voting rights, a pressing issue given that only about 20% of black people were registered to vote by 1957.However, the act faced considerable opposition in Congress, particularly from Southern Democrats who were engaged in a campaign of "massive resistance" against desegregation and civil rights reforms. Amendments like the Anderson–Aiken and O'Mahoney jury trial amendments were successful in diluting the act's potency. Senator Strom Thurmond notably conducted the longest one-person filibuster in Senate history in an attempt to block the legislation.Despite these setbacks, the act did pass, albeit in a watered-down form orchestrated by Senate Majority Leader Lyndon B. Johnson. While the act had a limited immediate impact on African American voter participation due to the removal of stringent voting protection clauses, it laid important groundwork for future civil rights legislation. It established the United States Commission on Civil Rights and the United States Department of Justice Civil Rights Division, both of which would play crucial roles in the enforcement of civil rights laws.The act also set the stage for more robust civil rights legislation in the 1960s, including the Civil Rights Act of 1960, the Civil Rights Act of 1964, the Voting Rights Act of 1965, and the Civil Rights Act of 1968. These later acts would build upon the foundation laid by the 1957 act, offering more comprehensive protections against discrimination and disenfranchisement. Overall, the Civil Rights Act of 1957 was a pivotal, if imperfect, step in the long journey toward civil rights and equality in America.The Biden administration has targeted 10 prescription drugs for price negotiations under Medicare, aiming to cut their costs by half on average by 2026. This move is part of Biden's Inflation Reduction Act, which was signed into law a year ago to address the high cost of medicines in the U.S. Among the drugs targeted are Eliquis, a blood thinner by Bristol-Myers Squibb and Pfizer, and AstraZeneca's Farxiga, which treats diabetes and heart failure. These drugs alone accounted for significant spending, with Eliquis costing Medicare $16 billion in the year through May 2023.Previously, the U.S. government was prohibited from negotiating drug prices due to a 2003 law that created Medicare's Part D program. However, the Inflation Reduction Act has mandated these negotiations. The drugs selected for this round of negotiations account for nearly $51 billion, or about 20% of Part D's prescription drug costs. Around 9 million people on Medicare took these drugs and paid $3.4 billion out-of-pocket last year.Pharmaceutical companies have criticized the move, arguing that it threatens innovation and intellectual property rights. Johnson & Johnson, which has two drugs on the list, stated that the policies put an "artificial deadline on innovation." The Pharmaceutical Research and Manufacturers of America (PhRMA) also warned that giving the government the power to set prices could have "significant negative consequences."The drug industry is currently suing to block these negotiations, and companies like Merck, Bristol, J&J, and AstraZeneca have each filed lawsuits. The U.S. Chamber of Commerce is also seeking an injunction to halt the negotiations. Analysts project a manageable impact on industry revenue, estimating as much as a 5% hit. However, the government expects that the price negotiations will save Medicare $100 billion through 2031.Bristol, Lilly Blockbusters Targeted for Medicare Price Cuts (1)US names first 10 drugs for Medicare price negotiation | ReutersU.S. states are increasingly focusing on "opportunity transparency" to address pay gaps, requiring companies to be more transparent about promotion opportunities. Illinois and Colorado have enacted laws that will take effect in 2025 and next year, respectively, mandating employers to disclose information about promotions. New Jersey also has pending legislation on this issue. These efforts build on pay disclosure laws initiated in Colorado in 2021 and later adopted by states like Washington, New York, California, and Hawaii. These laws primarily aim to address pay disparities affecting women and people of color.The new rules are designed to counter the "shoulder tap" practice, where employees are quietly selected for promotions, often without the knowledge of their co-workers. This lack of transparency disproportionately affects women and minorities. A 2022 study by McKinsey & Co. and LeanIn found that for every 100 men promoted from entry-level to manager positions, only 87 women and 82 women of color are promoted. This contributes to men holding nearly two-thirds of managerial roles despite making up only half of the workforce.Colorado's law imposes fines of up to $10,000 per violation and mandates changes in business practices. It requires companies to notify all employees of job openings and promotions in writing, giving them sufficient time to apply. Amendments to the law will further require businesses to notify employees about all job openings, not just promotions.The Illinois law, effective in 2025, will require companies to announce all potential promotions to their current employees within 14 days of posting a position externally. It will also require the disclosure of salary ranges and a summary of benefits in job ads. These laws aim to have a "cascading impact" on pay equity, complementing other policy efforts like banning employers from asking about applicants' prior salary history.States Put New Spin on Pay Gap Laws With Promotion TransparencyThe American Bar Association (ABA) is forming a new task force to explore the impact of artificial intelligence (AI) on the legal profession. This move comes as law firms increasingly experiment with AI tools like ChatGPT, while also confronting ethical and practical challenges posed by the technology. The ABA Task Force on Law and Artificial Intelligence will be chaired by Lucy Thomson, a lawyer and cybersecurity engineer based in Washington, D.C. The group will include seven special advisors, such as former U.S. Homeland Security Secretary Michael Chertoff and former U.S. Solicitor General Seth Waxman.The task force aims to assess how AI will affect the practice of law, probe ethical questions, and focus on issues like risk management, AI governance, and AI in legal education. ABA President Mary Smith emphasized the need to address both the "promise and the peril" of emerging technologies like AI. The initiative reflects a broader trend of growing interest in AI tools among legal professionals, including law schools considering the use of AI in applications and classrooms.By way of brief biographical background, Lucy Thomson, the group's chair, is the principal at a firm in Washington D.C., Livingston PLLC, that focuses on issues related to cyber security.Michael Chertoff was the co-author of the PATRIOT act, and former Secretary of Homeland Security under George W. Bush. Seth Waxman was Solicitor General of the United States from 1997 through 2001 and is frequently before the Supreme Court. The average age among the team is about 70, they're all lawyers, and none of them have any evident technical expertise.ABA taps prominent lawyers to tackle AI risks, opportunities | ReutersA U.S. District Judge, James Donato, is set to decertify a class-action lawsuit against Google involving 21 million consumers who claimed the tech giant violated federal antitrust laws through its Google Play app store. The decision could significantly reduce any damages that Google might owe for its distribution of Android mobile applications. The judge stated that his previous class certification order from November 2022 should be thrown out, as he decided not to allow an economist to testify as an expert witness for the consumers. This move eliminated an "essential element" of the consumers' argument for class certification. The class action had included consumers from 12 U.S. states and five territories, separate from a similar case brought by state attorneys general against Google.US judge set to decertify Google Play class action | Reuters Get full access to Minimum Competence - Daily Legal News Podcast at www.minimumcomp.com/subscribe

This episode is sponsored by Shopify. Shopify is a commerce platform that allows anyone to set up an online store and sell their products. It's the leading commerce platform designed for a business of any size. Whether you're selling online, on social media, or in person, Shopify has you covered on every base. With Shopify you can sell physical and digital products. You can sell services, memberships, ticketed events, rentals and even classes and lessons. Sign up for a $1 per month trial period at shopify.com/eyeonai   On episode #134 of the Eye on AI podcast, Craig Smith sits down with  Alex Zhavoronkov, founder and CEO of Insilico Medicine. Being at the forefront of cutting-edge drug discovery and longevity, Alex leverages the power of AI to develop novel drugs that could potentially extend our lifespan.  In this episode we explore the unique tools Insilico Medicine uses to hypothesize protein targets and their links to diseases. Alex also gives us a peek into their automated robotic lab in Suzhou, China, which is expected to revolutionize drug development.  We delve deep into the world of drug discovery, with a special focus on Insilico Medicine's tools, Pandomics, and Chemistry42, that are reshaping the field. Yet beyond the science, we also discuss the broader implications of tackling aging - from overpopulation to the strain on healthcare and social security systems. Finally, we tackle the elephant in the room - the challenges in the pharmaceutical industry. Can AI expedite the drug discovery process? Alex certainly thinks so. We explore how AI can help identify partners quickly, streamline processes, and ultimately accelerate the development of drugs.  Join us as we unravel these mysteries and take you through the fascinating world of biotech, AI, and pharmaceutical research.   (0:00) Preview (01:36) Shopify (04:26) AI's Revolutionizing Drug Discovery (06:11) Inside AI Pharmaceutical Research (12:23) Use of AI tools in Medicine (19:56) Biotech Synergy: Collaborative Exploration and Target Discovery (37:17) Decoding Aging with AI (46:52) Aging, Overpopulation, and Drug Breakthroughs (1:07:33) Pharmaceutical Industry Challenges (1:20:42) How AI is Advancing Longevity through Medicine    Craig Smith Twitter: https://twitter.com/craigss Eye on A.I. Twitter: https://twitter.com/EyeOn_AI

Listen now (2 mins) | Quick announcement: Drop Your Lawsuits, Drop Your Prices! Hightower is joining Public Citizen Texas, the Texas Organizing Project, Families USA and many more organizations on Wednesday, August 16th at the Federal Courthouse in Austin to demonstrate against Big Pharma’s greed. The Pharmaceutical Research and Manufacturers Association sued to prevent the Inflation Reduction Act from taking effect; many cities around the country are holding a series of actions calling on pharmaceutical corporations, PhRMA, the U.S. Chamber and other chambers of commerce to drop their lawsuits and instead negotiate lower drug prices.

The More Sibyl Podcast Presents: 아버지의 유산 | The Life and Works of the Late Rev. Paul Ogunyale: Pioneering Herbal Medicine for Sickle Cell Patients and the “NICOSAN” Saga: Episode 21 (2023)The name 'Ogunyale' will surely ring a bell for anyone in the herbal medicine field in Nigeria. This week, we have the privilege of welcoming Mr. Oluniyi (Niyi) Ogunyale to our show. He is the son of the late Reverend Paul Ogunniyi Ogunyale, a true legend in the herbal medicine field in Nigeria and the founder of Nicosan (now called Paumascel), a breakthrough drug for managing sickle cell disease. Niyi takes us on a captivating journey, sharing life experiences and insights from his childhood in Oyo town, Oyo state, Nigeria.During our conversation, we delve into the origin and history of the groundbreaking herbal drug and how his father founded it, including measures to prevent possible consumer addiction due to its alcohol content. We also explore the implications of the legal battle between the Ogunyales and the Nigerian Institute for Pharmaceutical Research and Development (NIPRD) over 'Nicosan.' Niyi shares his heartfelt account of the sad and heartbreaking events surrounding the case, shedding light on crucial details, including his father not signing the Memorandum of Understanding (MOU).Towards the end of the show, Niyi and I engage in a thought-provoking discussion about the implications of cultivating trust between the local community and industry, given the legal battles the family is going through. He also emphasizes the importance of ensuring the accessibility and affordability of his herbal medicines while maintaining their quality and effectiveness. Niyi envisions his brand and an extension of his father's legacy, Paumatree, gaining global recognition in the next 5-10 years, with a strong emphasis on retaining affordability and accessibility.We deeply appreciate your continued support and encourage you to stay tuned for more engaging upcoming episodes!

Best of Biotech from AZ Bio & Life Sciences to Jellatech - BRT S04 EP26 (189) 7-2-2023   What We Learned This Week: AZ Bio mission to improve life sciences, & make AZ a Top 10 Bioscience state Aqualung Therapeutics is treating inflammation in the lungs, get people off ventilators & save lives Calviri is working on a Vaccine to PREVENT Cancer, currently largest animal clinical trial Anuncia Medical has a Re-Flow product to help drain fluid from the brain, treats Hydrocephalus Collagen 2.0 – Innovation to Gelatin & gummies     Seg. 1 – Clips from:  AZ Bio & Life Sciences Innovation w/ Joan Koerber-Walker - BRT S04 EP10 (172) 3-5-2023   Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   LKIN: https://www.linkedin.com/in/joankoerberwalker  www.azbio.org Bio: As President and CEO of AZBio, Joan Koerber-Walker works on behalf of the Arizona Bioscience and Medical Technology Industry to support the growth of the industry, its members and our community on the local and national level. Ms. Koerber-Walker is also a life science investor and has served on the boards of numerous for-profit and non-profit organizations. In the life science industry, Ms. Koerber-Walker serves as as Arizona's representative to the State Medical Technology Alliance (SMTA), a consortium of state and regional trade associations representing their local medical technology companies which she chaired in 2015 and  represents Arizona as a member of the Council of State Bioscience Associations (CSBA) and the Coalition of State Bioscience Institutes (CSBI). Active in the entrepreneurial and investment communities, she also serves as Chairman of the Board of the Opportunity Through Entrepreneurship Foundation which provides entrepreneurial education, mentoring and support to at-risk members of the community, on the Board of Advisors to CellTrust, Inc. which provides secure communication technology to the healthcare industry, and as Chairman of CorePurpose, Inc. which she founded in 2002. Ms. Koerber-Walker has been recognized as Executive of the Year by the Arizona Society of Association Executives, as a “Most Admired Leader” by the Phoenix Business Journal (2015),  in the pages of AZ Business Leaders (2013 thru 2020), Most Influential Women in Arizona Business (2014) and is a 2 time National Finalist for the Stevie Award which recognizes the work of women in business. Her past experience includes two years as the CEO of ASBA (the Arizona Small Business Association), service as a member of the Board of Trustees of the National Small Business Association in Washington D.C., President of the National Speakers Association/Arizona, Chair of the Board of Advisors to Parenting Arizona, the state's largest child abuse prevention organization, & much more.     AZBio:  Supporting Arizona's Life Science Industry for 19 Years (2003 – 2022) Learn more about Arizona's bioindustry: www.azbio.org | Facebook: AZBIO |Twitter: @AZBio @AZBioCEO We're part of a movement to create sustainable funding for life science innovation in Arizona. Learn more at www.AZAdvances.org  MOVING LIFE SCIENCE INNOVATIONS ALONG THE PATH FROM DISCOVERY TO DEVELOPMENT TO DELIVERY OUR VISION OF THE FUTURE: Arizona is a top-ten life science state. OUR MISSION: AZBio supports the needs of Arizona's growing life science ecosystem. The Arizona Bioindustry Association (AZBio) is a not-for-profit, 501(c)6 trade association supporting the growth of Arizona's life science sector. AZBio  Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector.  As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.   AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations. Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.   Arizona's bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona's universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.   Full Show: HERE     Guest: Stan Miele President & CBO Aqualung Therapeutics Corp LKIN: HERE www.aqualungtherapeutics.com   Stan Miele Bio: A recognized global executive with success in sales, marketing and P&L leadership in the pharmaceutical/medical device and biotech industries. Mr. Miele was formally the Chief Commercial Officer at bioLytical Laboratories and Sucampo Pharmaceuticals Inc.  He was also President of Sucampo Pharma Americas for 6 years.   He was instrumental on some key licensing agreements for Sucampo, inclusive of the agreement with Abbott Japan, and also Takeda Pharmaceuticals (now Shire).  He is actively part of the team ensuring proper execution of clinical development, manufacturing, licensing, capital funding, alliances, and ensuring Aqualung meets all critical milestones.  He will be helping the company move toward accelerating the pipeline/platform technology and moving eNamptor™ toward commercialization.   Aqualung Therapeutics  Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension. Effective FDA-approved drugs are either currently unavailable or extraordinarily modest in their ability to modify disease progression. No drug is currently available that is preventive or curative. Aqualung's strategies, which include deployment of a human monoclonal antibody which targets a novel inflammatory mediator (nicotinamide phosphoribosyltransferase or NAMPT) will address the unmet need for novel, effective therapies for VILI, IPF, and pulmonary hypertension.   Full Show: HERE       Seg. 2 – Clips from:  Preventing Cancer with a Vaccine w/ Stephen Johnston of Calviri  - BRT S04 EP17 (179) 4-23-2023   Guest: Stephen Johnston Founding CEO, Calviri Inc.  LKIN: HERE https://calviri.com/   Bio: Chief Executive Officer & Chairman of the Board Stephen Albert Johnston is the inventor of the Calviri's central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics), Synbody Biotechnology and HealthTell, Inc. He is Director of the Arizona State University Biodesign Institute's Center for Innovations in Medicine and Professor in the School of Life Sciences. He has published almost 200 peer-reviewed papers and holds 45 patents. Prior to his appointment at ASU he was Professor and Director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University. He is a member of the National Academy of Inventors. Dr. Johnston received his B.S. and Ph.D. degrees from the University of Wisconsin.     Calviri Inc.  We are determined to offer humanity a better life, free from cancer. While our goal is hugely ambitious, we are intensely driven to rid the planet of worry from cancer. Calviri's mission is to provide affordable products worldwide that will end deaths from cancer. We are a fully integrated healthcare company developing a broad spectrum of vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. We focus on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer. The company is a spin out of the Biodesign Institute, Arizona State University, located in Phoenix, AZ. We have the largest dog vaccine trial in the world underway at three premier veterinary universities. The five-year trial will assess the performance of a preventative cancer vaccine.   Full Show: HERE       ReFlow to Help Treat Hydrocephalus w/ Elsa Abruzzo & Mark Geiger of Anuncia Medical - BRT S04 EP23 (186) 6-11-2023     Guest: Elsa Chi Abruzzo RAC, FRAPS – President Elsa Chi Abruzzo is a medical device executive, entrepreneur, and a founding member of Anuncia, Inc., Alcyone Therapeutics, Arthromeda, Inc. and Cygnus Regulatory. Elsa has a 30+ year successful product development, operations, regulatory, quality, and clinical track record in med tech Industries. Her experience includes leadership positions at Baxter, Cordis JNJ, CryoLife, Percutaneous Valve Technologies, AtriCure, InnerPulse, Merlin MD, Sapheon, and PTS Diagnostics. Elsa earned a BS in engineering from the University of Miami in Coral Gables, FL and is regulatory affairs certified and a Regulatory Affairs Professional Society Fellow, recognized for her leadership in Regulatory and Quality by MDDI.   https://anunciamedical.com/the-anuncia-story/#team https://www.linkedin.com/in/elsachiabruzzo/   https://anunciamedical.com/ About Anuncia Conceptualized in 2014 in collaboration with Boston Children's Hospital and spun out of Alcyone Therapeutics in 2018, Anuncia's patented portfolio of technologies are intended to provide peace-of-mind through innovation. Our core ReFlow™ technology uses a simple finger depression of a soft silicone dome located under the patient's scalp to produce a noninvasive, one-way flush of the patient's own CSF directed toward the ReFlow™ catheter to restore or increase CSF flow through a non-flowing shunt and potentially avoid emergency surgery.  Learn More     The name Anuncia comes from Panthera Uncia, the species name of the snow leopard. These animals live in mountainous regions of Asia and have been called by the World Wildlife Foundation “Guardians of the Headwaters” as they roam the headwater areas of the western basins. The origin of the word hydrocephalus comes from the Greek hudrokephalon, from hudro ‘water'+ kephalē ‘head'. The snow leopard, or Guardian of the Headwaters, is a symbol of Anuncia's dedication to improve daily quality of life for the millions of underserved patients with hydrocephalus and other CSF disorders, as well as their families, who suffer from the clinical, economic, and emotional burden of repeat revision brain surgery due to VP shunt occlusions.      Full Show: HERE       2nd Half – Clip from:  Cell Based Collagen from Jellatech + BRT 2.2021 - Best of Tech 2021 BRT S02 EP13 (60) 03-28-2021   Guests: Stephanie Michelsen, Co-Founder / CEO Jellatech https://www.jellatech.com/   Stephanie Michelsen, founder and CEO of Jellatech, aims to use biotechnology to synthesize animal proteins - without killing the animals. This includes collagen and gelatin produced from animal cell lines and cultured in giant bioreactors to be used in food, pharma and cosmetic applications. Jellatech has raised $2.1 million. The Raleigh-based startup CEO lauded, lands on Forbes 30 under 30 https://www.forbes.com/profile/stephanie-michelsen/?sh=1a4e74ed778c   Jellatech is a developer of cutting-edge technologies to produce high quality, pure, animal-free collagen and gelatin. Founded by a group of innovators, dreamers, entrepreneurs and scientists, Jellatech is on a mission to eliminate animals from the food system, making better ingredient products - starting with collagen and gelatin. Collagen is a by-product of the meat industry (protein in the body). You may be familiar with collagen from seeing it in skin serums, or with its derivative, gelatin, in gummy bears - but it's likely around you much more than you realize. This ingredient is used in a number of applications such as for food texturizers, vaccine stabilizers, pill capsules, the clarification of wine and beer, and many more.  Today, the only way to source native, functional collagen is to extract it from animals. This is what they are changing at Jellatech. Jellatech makes functional, native collagen - without animals. Cellular agriculture enables one to produce a more sustainable, smarter high quality collagen that breaks the cycle of relying on an inefficient and unethical supply chain of live animals.   Full Show: HERE       AZ Tech Council Shows:  https://brt-show.libsyn.com/size/5/?search=az+tech+council *Includes Best of AZ Tech Council show from 2/12/2023   Tech Topic: https://brt-show.libsyn.com/category/Tech-Startup-VC-Cybersecurity-Energy-Science  Best of Tech: https://brt-show.libsyn.com/size/5/?search=best+of+tech     ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the BRT Podcast.     Business Roundtable with Matt Battaglia The show where Entrepreneurs, High Level Executives, Business Owners, and Investors come to share insight and ideas about the future of business. BRT 2.0 looks at the new trends in business, and how classic industries are evolving.  Common Topics Discussed: Business, Entrepreneurship, Investing, Stocks, Cannabis, Tech, Blockchain / Crypto, Real Estate, Legal, Sales, Charity, and more…  BRT Podcast Home Page: https://brt-show.libsyn.com/ ‘Best Of' BRT Podcast: Click Here BRT Podcast on Google: Click Here BRT Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/podcast-brt-home/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/   Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.    

Today we are talking to Barry Greene, CEO of Sage Therapeutics. Barry has had an amazing career spanning over 30 years in the biotech industry. Prior to Sage Barry was President of Alnylam shepherding it with John through its evolution from basic science through commercial product launch. Prior to ALNY Barry was general manager of Oncology at Millennium where he was directly involved in the approval and launch of Velcade. He is currently a member of the board of the Pharmaceutical Research and Manufacturers of America. 

In this Minicast release, Fight Back revisits a conversation we had during the early days of the COVID-19 vaccine. We talked about how the vaccine was developed, how the clinical trial process works, and how herd immunity and vaccines work together. We were joined by vaccine expert Dr. Mike Ybarra, an Emergency Room physician and Vice President of Medical Affairs and Strategic Alliances at the Pharmaceutical Research and Manufacturers Association. Dr. Ybarra has over ten years of advocacy, health policy, and direct patient care experience. His background and knowledge help us take a closer look into the development of the COVID vaccine, its technology, and its implications for the public.

AZ Bio & Life Sciences Innovation w/ Joan Koerber-Walker - BRT S04 EP10 (172) 3-5-2023   Things We Learned This Week AZ Bio mission to improve life and bioscience, & make AZ a Top Ten Bioscience state Their company members deal with diseases, medical devices & cancer research to cure it Combo of Gov't & Private Funding, University research & private company work 3 Ds - Discovery, Development, & Delivery - takes years, and $ billions to bring new drugs to market       Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   LKIN: https://www.linkedin.com/in/joankoerberwalker  www.azbio.org Bio: As President and CEO of AZBio, Joan Koerber-Walker works on behalf of the Arizona Bioscience and Medical Technology Industry to support the growth of the industry, its members and our community on the local and national level. Ms. Koerber-Walker is also a life science investor and has served on the boards of numerous for-profit and non-profit organizations. In the life science industry, Ms. Koerber-Walker serves as as Arizona's representative to the State Medical Technology Alliance (SMTA), a consortium of state and regional trade associations representing their local medical technology companies which she chaired in 2015 and  represents Arizona as a member of the Council of State Bioscience Associations (CSBA) and the Coalition of State Bioscience Institutes (CSBI). Active in the entrepreneurial and investment communities, she also serves as Chairman of the Board of the Opportunity Through Entrepreneurship Foundation which provides entrepreneurial education, mentoring and support to at-risk members of the community, on the Board of Advisors to CellTrust, Inc. which provides secure communication technology to the healthcare industry, and as Chairman of CorePurpose, Inc. which she founded in 2002. Ms. Koerber-Walker has been recognized as Executive of the Year by the Arizona Society of Association Executives, as a “Most Admired Leader” by the Phoenix Business Journal (2015),  in the pages of AZ Business Leaders (2013 thru 2020), Most Influential Women in Arizona Business (2014) and is a 2 time National Finalist for the Stevie Award which recognizes the work of women in business. Her past experience includes two years as the CEO of ASBA (the Arizona Small Business Association), service as a member of the Board of Trustees of the National Small Business Association in Washington D.C., President of the National Speakers Association/Arizona, Chair of the Board of Advisors to Parenting Arizona, the state's largest child abuse prevention organization, & much more.     AZBio:  Supporting Arizona's Life Science Industry for 19 Years (2003 – 2022) Learn more about Arizona's bioindustry: www.azbio.org | Facebook: AZBIO |Twitter: @AZBio @AZBioCEO We're part of a movement to create sustainable funding for life science innovation in Arizona. Learn more at www.AZAdvances.org  MOVING LIFE SCIENCE INNOVATIONS ALONG THE PATH FROM DISCOVERY TO DEVELOPMENT TO DELIVERY OUR VISION OF THE FUTURE: Arizona is a top-ten life science state. OUR MISSION: AZBio supports the needs of Arizona's growing life science ecosystem. The Arizona Bioindustry Association (AZBio) is a not-for-profit, 501(c)6 trade association supporting the growth of Arizona's life science sector. AZBio  Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector.  As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.   AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations. Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.   Arizona's bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona's universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.         Notes:     Seg 1 – Flashback Clips of AZ Tech w/ Steve Zylstra (from 8/2/2020) & Russ Yelton (5/1/2022)   Guest: Steve Zylstra, President / CEO AZ Tech Council https://www.aztechcouncil.org/ https://www.aztechcouncil.org/kfnx_july2021/   Steve Zylstra of AZ Tech Council joins BRT to talk all things technology in the Valley. The Arizona Technology Council is one of the largest technology-driven trade associations in North America, with over 850 members and growing, the only organization specifically serving technology companies statewide. They protect innovators and truly believe that technology moves all of us forward; and are dedicated to the future of Arizona. Steve Zylstra advocates for AZ tech, as well as his recurring writing about the industry. Steve, and the Council are a major source for updates on technology, business growth, and what legislation is being drafted. Full Show: HERE     Guest: Russ Yelton, Pres., Yelton & Associates Immediate Past Chairman, AZBio Board of Directors http://www.yeltonandassociates.com/ https://www.azbio.org/azbio-board-of-directors/russ-yelton https://www.linkedin.com/in/russ-yelton-46a9412/ Russ Yelton served as Chairman of the AZBio Board of  Directors from January 2015 to December 2017.  He has been an active board members since being elected in 2009. He is currently president of Yelton and Associates.  The firm provides economic development services as well as early stage business solutions. Yelton and Associates has experience both domestically and internationally and has assisted thousands of entrepreneurs to raise funding and bring their products to a variety of markets. The firm  also has a long history of assisting municipalities with the development of co-work, incubators and accelerators as well as loan funds, student focused entrepreneurial programming as well as shared facilities.   Full Show: HERE     Seg 2 Joan joins BRT to talk about AZ Bio, and their mission to improve life and bio science -organization deals in medical devices, diseases, cancer research. Companies join AZ bio as members, 275+ in Arizona.   Examples: Calviri with their mission to end cancer, they are working on a vaccine to cure cancer. Currently, they are doing a study with dogs. Anuncia Medical working on helping kids who have hydrocephalus. Aqualung Therapeutics Corp. dealing with acute respiratory syndrome, which is fluid and inflammation in the lungs.   They have events monthly that are free and open to the public, running state wide AZ and in Phoenix. The 3rd Tuesday of every month, AZ Bio pairs. Quarterly events, the board hosts the reception at a member site, April 2023 at the Mayo Clinic. Bigger event in the fall (Sep 2023), 8th annual AZ Bio week   AZ Bio started in 2003, with the vision that Arizona will be a top 10 bioscience state. Partnerships with the major universities like ASU and U of A - researchers and service professionals at both universities.   Seg 3 Government is an important partner, that provides financial support. Examples are Medicare research, workforce help, and tax breaks. Many organizations like this are publicly funded with government and university help.   $25 billion in funding over the last 20 years in Arizona in bio investment. Government funded $5 billion, that's from state and federal sales tax at a penny per. $112 million funding to universities in 2022. Combination of industry, government and philanthropy.   Discovery phase - university helps develop the IP and research. Technology is spun out of the university to corporate development by companies. The AZ Board of Regents owns the patents. They license the patents to companies. Then you have regulatory.   Distribution of a product. Successful products are profitable. They have a royalty that pays to the company, the university and the government. Example of this was the University of Florida created Gatorade in the 1970s and still gets royalties today.   Process takes 10 to 15 years, with hundreds of people involved. Clinical trials of any type of drug takes years.   Calviri – targeted cancer therapeutics and cancer vaccines Skysong Innovations with ASU – office hub in Scottsdale with many bio-tech co's   Regulatory test of a product through the FDA to determine if it is safe and effective. This is a very expensive process with big clinical trials. Covid vaccine was a blockbuster hat. three to $4 billion in investment.   Seg 4 How do you define success? There's a 1 in 100 chance you help the patient. What is the ROI in Arizona - $25 bill invested. ROI has been $38 billion in 2021 in economic impact.   AZ ranks about 30th. To get in the top 10 needs to be about $78 billion of economic impact per year.   3 D's – Discovery. Development, Delivery   Step 1 - Most of 25 million invested in D1, university and hospital. Easy health industry trust fund, endowment.   Step 2 – Development - $10 million a year to get to 78 billion impact in 5 to 10 years, with public and private money.   Flynn Foundation is the steward of AZ Bio with the University. They are training the work force of tomorrow.   Companies to follow – Tripp, Medtronic, Rausch Industries (private) develop and deliver, they have the capital, they take the risk, and they have the work staff. It takes decades of work, investing and R&D plus regulations.   Covid saw a great breakthrough in bioscience with the MRNA vaccine development       AZ Tech Council Shows:  https://brt-show.libsyn.com/size/5/?search=az+tech+council *Includes Best of AZ Tech Council show from 2/12/2023   Tech Topic: https://brt-show.libsyn.com/category/Tech-Startup-VC-Cybersecurity-Energy-Science  Best of Tech: https://brt-show.libsyn.com/size/5/?search=best+of+tech     ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the BRT Podcast.     Business Roundtable with Matt Battaglia The show where Entrepreneurs, High Level Executives, Business Owners, and Investors come to share insight and ideas about the future of business. BRT 2.0 looks at the new trends in business, and how classic industries are evolving.  Common Topics Discussed: Business, Entrepreneurship, Investing, Stocks, Cannabis, Tech, Blockchain / Crypto, Real Estate, Legal, Sales, Charity, and more…  BRT Podcast Home Page: https://brt-show.libsyn.com/ ‘Best Of' BRT Podcast: Click Here BRT Podcast on Google: Click Here BRT Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/podcast-brt-home/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/   Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.  

Do you ever wonder why it takes so long for new drugs to hit the market? Have you ever questioned the efficiency of the pharmaceutical industry?Join me in this episode as we talk to Jack Scannell, a pharmaceutical industry expert, and discover the hidden efficiency secrets of drug development. In this episode, we delve into the critical factors that have shaped drug development over the last 60 years and analyze the industry's current state.Throughout the podcast, Jack draws on his extensive industry knowledge and provides insights on the importance of decision quality, the role of AI in drug discovery, and the economics of the research model.If you're looking to gain a better understanding of the pharmaceutical industry and its inner workings, join us in uncovering the efficiency secrets of drug development. Tune in to this episode.

Tonight ,on The Bow ,we return to THE EAT IT SERIES as we talk about UN SDGs 2 ZERO HUNGER and 3 GOOD HEALTH & WELL-BEING OF THE PEOPLEG.As one of Nigeria's advocates for ACT4FOOD ACT4CHANGE,we talk precisely about THE BLEND which is known in the Nigerian local palace as AGBO.Mixtures are not healthy at all.At THE BOW, we stand for healthy eating and drinking nutritious fluids.We reached out to our close friends & staff at NAFDAC and National Institute for Pharmaceutical Research and Development in the course of this production and they refused to grant us interview for over 3months (even after we gave them time for Right Of Response).. Please listen to this episode by visiting The Bow https://anchor.fm/THE-BOW Thank you. --- Support this podcast: https://podcasters.spotify.com/pod/show/THE-BOW/support

In this week's episode, Jonathan Sackier is joined by Annalisa Jenkins, a biopharma thought leader with over 25 years of experience in the industry.  The pair discuss Jenkins'  time in the Royal Navy, her role as non-executive director of Genomics England, and how connecting human and financial capital can help create an environment conducive to success.

On this week's episode of Kathryn For Real, Kathryn sits down with Pharmacologist and Health and Wellness advocate Dr. Tyler Panzner. After suffering from anxiety and depression in the early stages of obtaining his PhD, Tyler became fascinated with how the brain can be modulated to alter your consciousness and behavior.   Forgoing a career within Pharmaceutical Research and Development he adopted a "natural first" approach to holistic medicine. Dr. Panzner is driven to not only enhance his own life but enhance the lives around him by creating awareness on holistic biological principles to ensure healthy living. Listen to this week's episode to learn what holistic principles you can adopt to ensure healthy living in all aspects of life!

Be on the lookout for outcome manipulation! Pharmaceutical companies are important innovators, but they are businesses first. In this episode, renowned pharmaceutical critic, Dr. Daniel Carlat, gives us tips on spotting common research methods used to bias findings. Hosts: Al, Toshia Guests: Daniel Carlat, MD, Yasmine Dakhama, MS4

QUESTION PRESENTED: Whether allegations that a state law has dramatic economic effects largely outside of the state and requires pervasive changes to an integrated nationwide industry state a violation of the dormant commerce clause, or whether the extraterritoriality principle described in the Supreme Court's decisions is now a dead letter; and   whether such allegations, concerning a law that is based solely on preferences regarding out-of-state housing of farm animals, state a claim under Pike v. Bruce Church, Inc. Date                 Proceedings and Orders (key to color coding)Sep 27 2021 | Petition for a writ of certiorari filed. (Response due October 29, 2021)Oct 11 2021 | Waiver of right of respondents Karen Ross, in her official capacity as Secretary of the California Department of Food and Agriculture, et al. to respond filed.Oct 11 2021 | Waiver of right of respondents Humane Society of the United States, et al. to respond filed.Oct 12 2021 | Blanket Consent filed by Petitioner, National Pork Producers Council, et al.Oct 13 2021 | DISTRIBUTED for Conference of 10/29/2021.Oct 13 2021 | Waiver of National Pork Producers Council, et al. of right to respond not accepted for filing. (October 19, 2021)Oct 19 2021 | Response Requested. (Due November 18, 2021)Oct 29 2021 | Brief amicus curiae of Canadian Pork Council filed.Nov 01 2021 | Motion to extend the time to file a response from November 18, 2021 to December 20, 2021, submitted to The Clerk.Nov 01 2021 | Response to motion for an extension of time from petitioner National Pork Producers Council, et al. filed.Nov 02 2021 | Motion to extend the time to file a response is granted in part and the time is extended to and including December 8, 2021, for all respondents.Nov 10 2021 | Brief amici curiae of Indiana, et al. filed.Nov 12 2021 | Brief amicus curiae of Cato Institute filed.Nov 18 2021 | Brief amici curiae of North Carolina Chamber Legal Institute, et al. filed.Nov 18 2021 | Brief amici curiae of National Association of Manufacturers, et al. filed.Nov 18 2021 | Brief amici curiae of Iowa Pork Producers Association, et al. filed.Dec 08 2021 | Brief of respondents Karen Ross, in her official capacity as Secretary of the California Department of Food and Agriculture, et al. in opposition filed.Dec 08 2021 | Brief of respondents Humane Society of the United States, et al. in opposition filed.Dec 21 2021 | Reply of petitioner National Pork Producers Council, et al. filed. (Distributed)Dec 22 2021 | DISTRIBUTED for Conference of 1/7/2022.Jan 10 2022 | DISTRIBUTED for Conference of 1/14/2022.Jan 18 2022 | DISTRIBUTED for Conference of 1/21/2022.Feb 11 2022 | DISTRIBUTED for Conference of 2/18/2022.Feb 22 2022 | DISTRIBUTED for Conference of 2/25/2022.Feb 28 2022 | DISTRIBUTED for Conference of 3/4/2022.Mar 14 2022 | DISTRIBUTED for Conference of 3/18/2022.Mar 21 2022 | DISTRIBUTED for Conference of 3/25/2022.Mar 28 2022 | Petition GRANTED.Apr 06 2022 | Joint motion for an extension of time to file the briefs on the merits filed.Apr 22 2022 | Joint motion to extend the time to file the briefs on the merits granted. The time to file the joint appendix and petitioners' brief on the merits is extended to and including June 10, 2022. The time to file respondents' briefs on the merits is extended to and including August 8, 2022.Apr 25 2022 | Motion to dispense with printing the joint appendix filed by petitioners National Pork Producers Council, et al.May 16 2022 | Motion to dispense with printing the joint appendix filed by petitioner GRANTED.Jun 10 2022 | Brief of petitioners National Pork Producers Council, et al. filed.Jun 14 2022 | ARGUMENT SET FOR Tuesday, October, 11, 2022.Jun 14 2022 | Brief amicus curiae of Pacific Legal Foundation filed.Jun 17 2022 | Brief amici curiae of National Association of Manufacturers, et al. filed.Jun 17 2022 | Brief amicus curiae of Protect the Harvest filed.Jun 17 2022 | Brief amicus curiae of The Buckeye Institute filed.Jun 17 2022 | Brief amici curiae of North Carolina Chamber Legal Institute, et al. filed.Jun 17 2022 | Brief amici curiae of The Retail Litigation Center, Inc., et al. filed.Jun 17 2022 | Brief amicus curiae of Professor Lea Brilmayer in support of neither party filed.Jun 17 2022 | Brief amici curiae of Canadian Pork Council, et al. filed.Jun 17 2022 | Brief amicus curiae of American Association of Swine Veterinarians filed.Jun 17 2022 | Brief amici curiae of Indiana, et al. filed.Jun 17 2022 | Brief amici curiae of Agricultural And Resource Economics Professors in support of neither party filed.Jun 17 2022 | Brief amicus curiae of Pharmaceutical Research and Manufacturers of America filed.Jun 17 2022 | Brief amici curiae of Professors Michael Knoll, et al. filed.Jun 17 2022 | Brief amicus curiae of The Chamber of Commerce of the United States of America filed.Jun 17 2022 | Brief amici curiae of Iowa Pork Producers Association, et al. filed.Jun 17 2022 | Brief amicus curiae of North American Meat Institute filed.Jun 17 2022 | Brief amicus curiae of Washington Legal Foundation filed.Jun 17 2022 | Brief amicus curiae of Association for Accessible Medicines filed.Jun 17 2022 | Brief amicus curiae of United States filed.Jun 17 2022 | Brief amicus curiae of National Taxpayers Union Foundation filed.Jun 17 2022 | Brief amici curiae of Association Des Éleveurs De Canards Et D'oies Du Québec, et al. filed.Jun 22 2022 | Record requested from the 9th Circuit.Jun 23 2022 | The record from the U.S.C.A. 9th Circuit is electronic and located on Pacer.Jul 21 2022 | CIRCULATEDAug 04 2022 | Brief amicus curiae of Dr. Leon Barringer filed. (Distributed)Aug 08 2022 | Brief of State Respondents filed. (Distributed)Aug 10 2022 | Motion for leave to file respondents' brief on the merits out of time filed by respondents The Humane Society of the United States, et al.Aug 10 2022 | Brief of respondents The Humane Society of the United States, et al. filed (September 9, 2022). (Distributed)Aug 12 2022 | Brief amici curiae of State of Illinois, et al. filed. (Distributed)Aug 12 2022 | Brief amici curiae of The Center for a Humane Economy, et al. filed. (Distributed)Aug 15 2022 | Motion for divided argument filed by respondents The Humane Society of the United States, et al.Aug 15 2022 | Motion of the Solicitor General for leave to participate in oral argument as amicus curiae, for divided argument, and for enlargement of time for oral argument filed.Aug 15 2022 | Brief amici curiae of Animal Protection Organizations and Law Professors filed. (Distributed)Aug 15 2022 | Brief amici curiae of Worker Safety Advocates filed. (Distributed)Aug 15 2022 | Brief amici curiae of Donald Broom, Elena Contreras, Gwendolen Reyes-Illg, James Reynolds, and 374 Additional Animal-Welfare Scientists and Veterinarians filed. (Distributed)Aug 15 2022 | Brief amicus curiae of Animal Protection and Rescue League, Inc. filed. (Distributed)Aug 15 2022 | Brief amicus curiae of The American Society For The Prevention of Cruelty to Animals filed. (Distributed)Aug 15 2022 | Brief amici curiae of Professors Barry Friedman and Daniel T. Deacon filed. (Distributed)Aug 15 2022 | Brief amicus curiae of Trade Law Professor Mark Wu filed. (Distributed)Aug 15 2022 | Brief amici curiae of National League for Cities, et al. filed. (Distributed)Aug 15 2022 | Brief amicus curiae of United States Senator Cory Booker filed. (Distributed)Aug 15 2022 | Brief amici curiae of Jim Keen DVM PH.D, et al. filed. (Distributed)Aug 15 2022 | Brief amici curiae of O. Carter Snead, Mary Eberstadt, and Matthew Scully filed. (Distributed)Aug 15 2022 | Brief amici curiae of Economic Research Organizations filed. (Distributed)Aug 15 2022 | Brief amici curiae of American Public Health Association, et al. filed. (Distributed)Aug 15 2022 | Brief amicus curiae of Public Citizen filed. (Distributed)Aug 15 2022 | Brief amici curiae of Federalism Scholars filed. (Distributed)Aug 15 2022 | Brief amicus curiae of Perdue Premium Meat Company Inc. d/b/a Niman Ranch filed. (Distributed)Aug 15 2022 | Brief amici curiae of Global Animal Partnership and EarthClaims LLC filed. (Distributed)Aug 15 2022 | Brief amicus curiae of Physicians Committee For Responsible Medicine filed. (Distributed)Aug 15 2022 | Brief amicus curiae of Northeast Organic Dairy Producers Alliance filed. (Distributed)Aug 15 2022 | Brief amici curiae of Small and Independent Farming Businesses, et al. filed. (Distributed)Aug 15 2022 | Brief amici curiae of Historians Thomas Aiello and Joshua Specht filed. (Distributed)Aug 15 2022 | Brief amicus curiae of Association of California Egg Farmers filed. (Distributed)Aug 15 2022 | Brief amicus curiae of ButcherBox filed. (Distributed)Aug 15 2022 | Brief amici curiae of Constitutional Law Scholars filed. (Distributed)Sep 07 2022 | Reply of petitioners National Pork Producers Council, et al. filed. (Distributed)Sep 09 2022 | Motion for leave to file respondents' brief on the merits out of time GRANTED.Sep 09 2022 | Motion for divided argument filed by respondents GRANTED.Sep 09 2022 | Motion of the Solicitor General for leave to participate in oral argument as amicus curiae, for divided argument, and for enlargement of time for oral argument GRANTED, and the time is divided as follows: 20 minutes for petitioners, 15 minutes for the Solicitor General, 25 minutes for the state respondents, and 10 minutes for The Humane Society of the United States, et al. respondents.

Dr. Ashana Puri talks about her fascinating research into transdermal drug delivery systems and keys to success in her Pharmacy Calculations course.

There's a lot of talk about DNA testing, but how effective and accurate is it really in addressing health concerns like chronic poor sleep? This week Dr. Porter sits down with Harris Khan from The DNA Company to discuss how using intelligent DNA testing can help build a precision-based approach to addressing chronic conditions, including poor sleep, by focusing on outcomes rather than genes and building in behavioral change to initiate sustainable, long-term health and wellness optimization. Harris holds a Bachelor of Science in Honors Biomedical Sciences from the University of Waterloo. After completing his undergraduate studies, he pursued post-graduate studies in Pharmaceutical Research and Development, before gaining employment at Apotex, Canada's largest generic pharmaceutical company, in the Formulations Development department. Harris was a key member of the team that would test initial formulations for billion-dollar drugs in their infancy stages. He left Apotex to co-found Youtrients, now The DNA Company, where he established an ISO-7, GMP-compliant nutraceutical compounding facility. As The Director of Product Development for The DNA Company, Harris oversees the entire lifecycle of The DNA Company's suite of products and services. In collaboration with industry experts and clinicians, he spearheaded the development of The DNA Company's proprietary genomic algorithms based on metanalyses of thousands of genomic data points. He is a co-author of patents in the field of functional genomics and speaks on behalf of The DNA Company at events and conferences worldwide. One of Harris's favorite health hacks includes eating dates during periods of heavy mental or physical activity. Says Harris: “They're an incredible source of nutrients and improve water retention. There's a reason they grow in arid environments like desserts! Two to three dates in the morning can be nutritionally fulfilling and provide the necessary glucose your brain needs to function throughout the day.” What you'll learn: • Why most DNA tests are confusing • How choosing the right DNA test provider can help you solve your health problems • How genetics contribute to, but do not define, a person's potential • Strategies to optimize genetic variations • How behavioral changing solves the problem of what's next after DNA testing Check out the DNA Company Here: Web: www.thednacompany.com Social: @thednaco Special Offer: Thednacompany.com/sleepwell

Researchers have discovered how to use evolutions deadliest and oldest weapon for good. But how can scientists create medicine from lethal venom? Dr. Leslie Boyer reveals the entire process and explains why horses are so valuable to the research.   Learn more at: https://radiohealthjournal.org/venom-research-lethal-weapon-or-medical-miracle/

Catch the Ask AI interview with Liran Belenzon, co-founder & CEO of BenchSci, the AI-assisted application accelerating science at 16 of the top 20 pharmaceutical companies and over 4,500 research centers worldwide. Visit our episode post to get all the links.

In this episode of Black Power Moves, part of the Ebony Covering Black America Podcast Network, we're speaking to Donna Cryer, Founder, President & Chief Executive Officer of Global Liver Institute. https://www.globalliver.org/ GLI is the premier patient-driven liver health nonprofit operating across the globe. Moved by her own experience as a liver transplant recipient, Donna has become a powerful force in liver health, health policy, and patient advocacy. At GLI, she has raised more than $10 million for liver health initiatives. She has been featured by and worked with Congress and the White House to advance equitable healthcare in both organ procurement and information technology. Donna is a frequent speaker on patient centricity in research and healthcare delivery and patient engagement in healthcare transformation at meetings of Biotechnology Innovation Organization, Pharmaceutical Research and Manufacturers of America, America's Health Insurance Plans, National Quality Forum, National Comprehensive Cancer Network®, and the National Academy of Medicine.  She frequents the stage of national platforms, including The Washington Post Live, SXSW, and The Atlantic's People v. Cancer. Learn more about your ad choices. Visit megaphone.fm/adchoices

My guest today is Harris Khan, Co-Founder of The DNA Company. I feel very lucky to get to meet some exceptional companies that I believe are real game-changers in helping people exponentially improve their lives - and this is one of them! What's so exciting about knowing your DNA? It's knowing that your DNA isn't rigid but can be, like light switches, turned on and off based on things you do which is really empowering. Every cellular process in your body is instructed by the 22,000 genes that make up your genetic code.  The DNA Company have figured out through their advanced DNA test exactly what genes you have and what supplements, diet, lifestyle, and environment are right specifically for you. That way, you can keep the “bad genes” turned off and optimize your health for longer - think preventing disease, slowing aging and optimizing performance. *** Also for you, dear audience, The DNA Company is offering my audience $50 off your advanced DNA test by going to TheDNACompany.com/Claudia today! *** Harris holds a Bachelor's of Science in Honours Biomedical Sciences from the University of Waterloo. After completing his undergraduate studies, he pursued post-graduate studies in Pharmaceutical Research and Development, before gaining employment at Apotex, Canada's largest generic pharmaceutical company, in the Formulations Development department. Harris was a key member of the team that tested initial formulations for drugs in their infancy stages. He went on to co-found The DNA Company, where he established an ISO-7, GMP compliant nutraceutical compounding facility. He currently serves as The Director of Product Development, where he oversees the entire lifecycle of The DNA Company's suite of products and services. In this episode, we dig into Harris' background and the mission of The DNA Company, the science behind how our DNA can be adapted and optimized, the process behind it, the benefits in health optimization including the anti-aging benefits, male vs. female health implications, detoxification as well as the best strategies people can do based on their DNA results to optimize their health for longer. Before we begin, please hit SUBSCRIBE to the podcast to get your weekly dose of longevity & lifestyle inspiration and SHARE the episode with those you love!  I would also love to hear from you so please leave a comment to let me know what you think or reach out on Instagram @longevityandlifestyle! Please enjoy! — If you enjoyed the podcast episode, please consider leaving a short review! It takes a few seconds but means the world to me to get the best guests and content for you and I love reading your reviews! Thank you!  Follow Claudia on: Instagram: instagram.com/longevityandlifestyle Facebook: facebook.com/longevityandlifestyle YouTube: youtube.com/channel/UCZF-s8jsUejc0TpVqnFE1lQ LinkedIn: linkedin.com/company/longevity-lifestyle Twitter: twitter.com/LongevityLifest Past guests on The Longevity & Lifestyle Podcast include Dr. David Perlmutter, Dr. Amy Killen, Sergey Young, Dr. Dale Bredesen, Dr. Kristen Willeumier, Dr. Louise Newson, Dr. Kien Vuu, Dr. Carolina Reis, Nikolina Lauc, Mohamed Massaquoi, Nick Potter, Dr. Pamela Kryskow, Harris Khan, Dr. Julia Mirer, Isabella Channing, Dina Burkitbayeva, Mario Chamorro, Mariko Bangerter, Dr. Stephanie Manson Brown, Dr. Mohammed Enayat, Helen Reavey, Elena Letyagina, and many more!

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Hanns-Christian Mahler CEO at ten23 health. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Hanns, covering: Transitioning from the structure and scale of Merck, Roche and Lonza into an entrepreneurial start-up CDMO leader. Having a business purpose focused on the triple-bottom line that is not just profit - patients, people and planet. Tips and insights of how a CDMO can play its part in encouraging sustainability, reducing environmental impact and managing footprints, across all levels. Insights into the opportunity and growth in small-scale sterile biologics, and some of the drivers behind these trends. Dr. Mahler is CEO & Board Member at ten23 health. He previously led the Drug Product Services (DPS) Business Unit at Lonza and worked in various leadership roles at Roche and Merck. He has an extensive expertise in formulation development, process development & validation, packaging/device development and integration, sterile manufacturing, and regulatory submissions. With a Ph.D. in toxicology, he also serves as Editor for Pharmaceutical Research, Journal of Pharmaceutical Sciences, AAPS Open Journal, and PDA Journal of Pharmaceutical Sciences & Technology. He has published more than 120 manuscripts and is co-inventor of more than 50 patents. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

Today we're talking to Robert Niichel the CEO of SmartTab, which is creating ingestible capsules for drug delivery of biologics and targeted medications. Think of a pill you take that tells medications where to deliver their remedy. It's like an Uber driver or GPS for drug therapy.  About SmartTab: SmartTab is developing an advanced platform of ingestible capsules for oral drug delivery of biologics and targeted medications. The platform is intended to replace both traditional coated capsules and injections. We're on a mission to provide novel administration routes and effective therapies that improve patient lives. About Robert:Robert Niichel has 20+ years of experience in Pharmaceutical Research and Development, holding numerous pharma delivery system patents issued and pending in the United States and Globally. Niichel started SmartTab in 2016 as an evolution of his prior startup company which brought pharmaceutical technologies into the sports nutrition and consumer healthcare space.Resource links: http://smarttab.co/https://www.linkedin.com/in/robert-niichel-54a48038/https://www.linkedin.com/company/veloce-corporationhttps://twitter.com/Veloce_SmartTabQualioApply to be on the show: https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez

Harris Khan holds a Bachelor's of Science in Honours Biomedical Sciences from the University of Waterloo. After completing his undergraduate studies, he pursued post graduate studies in Pharmaceutical Research and Development, before gaining employment at Apotex, Canada's largest generic pharmaceutical company, in the Formulations Development department. Harris was a key member of the team that would test initial formulations for billion-dollar drugs in their infancy stages. He left Apotex to co-found Youtrients, now The DNA Company, where he established an ISO-7,  GMP-compliant nutraceutical compounding facility. He currently serves as The Director of Product Development, where he oversees oversees the entire lifecycle of The DNA Company's suite of products and services. For information about ordering a test as a consumer head to www.TheDNACompany.com. If you are a provider looking to create a practitioner account, head to www.DNA.clinic.   Thanks so much for listening and you know I want to help you have a healthy business inside and out! If you have been trying to market and sell your services and things just aren't clicking for you, then we would like to help you have a MAJOR shift and feel completely confident in how you move people through a health journey.  I want to invite you to take advantage of a special FREE Health Program Discovery session where you will work together with one of our coaches to... Create an empowering vision for your health business success  Find hidden barriers that may be limiting your growth  Feel the confidence successful health providers embody in their business and grab some inspiration for yourself to have a highly converting, extraordinarily successful signature health program Head over to SarahTugender.com/workwithsarah to grab one of our limited spots.

Oral argument argued before the Eighth Circuit U.S. Court of Appeals on or about 12/15/2021

Pharmaceutical Research v. Stuart Williams

Grape seed extract found to extend lifespan of old mice Chinese Academy of Sciences and Mayo Clinic, December 7, 2021 A team of researchers affiliated with a host of institutions in China and the U.S. has found that injecting procyanidin C1 (PCC1), a chemical found in grape seed extract, into older mice extended their lifespan. In their paper published in the journal Nature Metabolism, the group describes the link between PCC1 and extended lifespan in mice and the experiments they carried out with the material. The researchers screened 46 plant extracts looking for anti-aging capabilities. They came across PCC1. Initial tests during screening showed it reduced the number of senescent cells in the human prostate. Such cells are known to contribute to aging. Intrigued with their results, the researchers tested it further. They found that at low doses it prevented senescent cells from contributing to inflammation, and at higher doses killed them outright without harming other cells. (NEXT) Gratitude may improve your health University of Michigan and University of California, San Francisco, December 6, 2021 Be thankful for what you have—it might improve your physical and mental health, according to a new global study that uses cell phone data. People who were more grateful had lower blood pressure and heart rate, as well as greater feelings of appreciation toward others. The study found that optimism was also linked to health and mental benefits, such as better sleep quality and more positive expectations and reflections. The findings showed that gratitude and optimism are positive psychological dispositions associated with beneficial outcomes. Gratitude highlighted the positive aspects of the day, whereas optimism minimized the negative aspects of the day, the study indicated. In addition, optimism was a better predictor of sleep quality and stress frequency and intensity than gratitude. (NEXT) Higher physical activity is associated with a better metabolic health risk factor profile in menopausal women University of Jyvaskyla (Finland), November 29, 2021 A study conducted at the University of Jyväskylä shows that menopausal transition is associated with unfavourable changes in metabolic health that may be mitigated with a physically active lifestyle. Especially, physical activity alleviated the increase in systolic blood pressure. In the study, the women were divided into three groups based on the change in their menopausal status during the follow-up period and the groups were compared to each other. Body composition, waist circumference, blood pressure, blood lipids and glucose and physical activity were measured twice during the four-year follow-up time. In all groups, the levels of several metabolic health indicators deteriorated. (NEXT) Could glucosamine and chondroitin support a healthy colon? Memorial Sloan Kettering Cancer Center, December 6, 2021 Use of the supplements, which are used for joint health support, was associated with a 23% reduction in the risk of colorectal cancer, according to data from the Nurses' Health Study and Health Professionals Follow-up Study published in the International Journal of Cancer . “Results of this study suggest a potential beneficial effect of glucosamine and chondroitin supplementation on risk of colorectal cancer, and further support the previously observed association between use of these supplements and risk of colorectal cancer in the VITAL study,” wrote the researchers. “Additional study is needed to better understand the association between use of glucosamine and chondroitin and risk of colorectal cancer, and the mechanisms by which these supplements may affect risk of colorectal cancer.” (NEXT) Cannabis impacts sperm counts, motility in two generations of mice Washington State University, December 2, 2021 An intense but short-term exposure to cannabis vapor lowered sperm counts and slowed sperm movement, or motility, not only in the directly exposed male mice but also in their sons. The Washington State University study, published in the journal Toxicological Sciences, builds on other human and animal studies, showing that cannabis can impede male reproductive function. The current study uses more controlled circumstances than human studies, which often have to rely on surveys, and is the first known reproductive study to use vaporized whole cannabis in mice, which is the more common form humans use. (NEXT) Study suggests giving kids too many toys stifles their creativity University of Toledo, December 6, 2021 A team of researchers at the University of Toledo has found that children are more creative when they have fewer toys to play with at one time. In their paper published in the journal Infant Behavior and Development, the group describes their observational study of toddlers at play, what they learned and offer some suggestions for parents. The researchers found that the toddlers playing with four toys engaged in more creative activities than did the toddlers who had 16 toys to choose from. They also found, unsurprisingly, that toddlers with fewer options tended to play with each of the toys available to them for a longer amount of time. Much of that additional time, the researchers noted, was taken up with finding news ways to play with them. (OTHER NEWS NEXT) TO WATCH THE VIDEO PART OF THE GARY NULL SHOW GO TO PROGRESSIVERADIONETWORK.COM (NEXT) Rap Sheets for Pfizer and J&J PFIZER Rejected the government for distributing the vaccine… will do it itself CEO Albert Bouria – before reining the closing bell at stock exchange.. stated that those who do not vaccinated will be the weak links in stopping the pandemic Pfizer – second largest drug/biotech co in world – 4th highest earner in vaccines Product safety – it is heart valves were defected and caused a hundred deaths – investigation found company intentionally misled regulators knowing about hazards Celebrex.. in wake of vioxx – painkiller.. admitted in its trials the drug increased heart problems.  Settled 894 million – for Celebrex and Bextra (painkiller that causes cardio and GI risks) More recent – 1000 lawsuits or birth defects associated with its drug Zolof… Price fixing – as far back as 1950s with antibiotics. Such as tetracycline Price fixing over the years… AIDS drug, Lipitor (cholesterol drug) In 2016 the Justice Department announced that Pfizer would pay $784 million to settle allegations that it underpaid rebates to Medicaid on two of its drugs. 20 million paid to 4500 doctors for speaking on behalf of its drugs Busted for false Centrum claims for breast and colon health Racketeering fraud over Neurtonin – epilepsy drug Bribery – payments to foreign government officials.. and  bribing overseas doctors to increase foreign sales Selling off label Kickbacks from medicare Tax avoidance – using paper work to “relocate” to Ireland , tax haven Repeatedly paid fines for environmental violations at its research and manufacturing plants. In 2009 - dubious distinction of paying the largest-ever criminal fine at the time — $2.3 billion — for fraudulent and illegal promotion of four drugs, including a painkiller marketed at “dangerously high” doses. In 2016, a British regulator levied a $106 million fine against Pfizer for a 2600% increase in the price of a widely prescribed anti-epilepsy drug that increased the National Health Services' expenditures from one year to the next — for a single drug—from $2.5 million to $63 million. Pfizer is the top drug company spender in state elections, even outspending the industry's own lobbying group, Pharmaceutical Research and Manufacturers of America (PhRM). In 2014 Pfizer launched an effort to take over AstraZeneca that was designed not only to swallow a competitor but also to cut its tax bill by locating the headquarters of the combined operation in Britain. When AstraZeneca resisted the controversial move, Pfizer abandoned the bid. Then in November 2015 Pfizer announced a similar deal, worth $160 billion, to merge with Allergan and move the headquarters of the combined company to Ireland. The plan was dropped when the Obama Administration introduced new tax rules. JOHNSON AND JOHNSON In 2004 J&J agreed to pay up to $90 million to settle lawsuits linking the prescription heartburn medication Propulsid to several hundred deaths and many more cases of cardiac irregularity. During 2009 and 2010 the company had to announce a string of recalls of medications, contact lenses and hip implants. The most serious of these was the massive recall of more than 136 million bottles of liquid Tylenol and Motrin for infants and children after batches of the medications were found to be contaminated with metal particles. The company's handling of the matter was so poor that J&J subsidiary McNeil-PPC became the subject of a criminal investigation and later entered a guilty plea and paid a criminal fine of $20 million and forfeited $5 million. It also came out during a Congressional investigation of the matter that in 2008 J&J had engaged in what was labeled a "phantom recall." When faced with Motrin IB caplets that were not dissolving property, McNeil hired contractors to buy up the products in stores while making no announcement to the public. In 2013 J&J reached a deal with plaintiffs lawyers under which it would pay nearly $2.5 billion in compensation to an estimated 8,000 people who had received flawed hip implants. In 2016 two juries awarded a total of $127 million damages to women who sued J&J claiming that their ovarian cancer was caused by the talc in J&J Baby Powder. An award of $417 million was made by a California jury in 2017 and a verdict of more than $4 billion was awarded in Missouri in 2018 (an appeal court later reduced that to $2.1 billion). The New York Times reported in December 2018 that internal company memos from the 1970s discussed the possibility that its talcum powder could contain asbestos. In 1996 J&J reached a settlement with the Federal Trade Commission under which the company agreed to stop making what the agency called false claims about the failure rates of condoms in the marketing of its K-Y spermicidal lubricant. In 2010 J&J subsidiaries Ortho-McNeil Pharmaceutical and Ortho-McNeil-Janssen had to pay $81 million to settle charges that they promoted the epilepsy drug Topamax for uses not approved as safe by the Food and Drug Administration The following year, J&J subsidiary Scios Inc. had to pay $85 million to settle similar charges relating to its heart failure drug Natrecor. In 2013 the Justice Department announced that J&J and several of its subsidiaries would pay more than $2.2 billion in criminal fines and civil settlements to resolve allegations that the company had marketed its anti-psychotic medication Risperdal and other drugs for unapproved uses as well as allegations that they had paid kickbacks to physicians and pharmacists to encourage off-label usage In a related Risperdal civil lawsuit, a jury later awarded $8 billion in damages but a Philadelphia judge reduced that by more than 99 percent to $6.8 million. In 2019 J&J and its subsidiary Ethicon, Inc. agreed to pay over $116 million to 41 states and the District of Columbia to settle litigation alleging deceptive marketing of transvaginal surgical mesh devices. In a separate suit brought by California, a state judge ordered the company to pay $344 million. In 2021 J&J reached an agreement with a group of states under which it would pay $5 billion to resolve litigation brought against its subsidiary Janssen Pharmaceuticals alleging improper sale of pain medications, contributing to the national opioid epidemic. In 2001 J&J agreed to pay up to $860 million to settle a class-action lawsuit alleging that the company had misled consumers into prematurely throwing away disposable Acuvue contact lenses. The suits argued that the company drove up sales of its 1-Day Acuvue soft lenses by recommending that consumers use them only once, even though the product was identical to regular Acuvue lenses, which could be worn as long as two weeks. In 2011 J&J agreed to pay a $21.4 million criminal penalty as part of a deferred prosecution agreement with the Justice Department resolving allegations of improper payments by J&J subsidiaries to government officials in Greece, Poland and Romania in violation of the Foreign Corrupt Practices Act. (NEXT) Weapons trade booms as profits hit record $531bn in 2020 Swedish think tank says world's 100 biggest arms firms were largely shielded from the effect of the pandemic. AL JAZEERA. 6 Dec 2021 Sales of weapons and military services by the world's 100 biggest arms companies reached a record $531bn in 2020, an increase of 1.3 per cent in real terms compared with the previous year, according to the Stockholm International Peace Research Institute (SIPRI). The Swedish think tank said 2020 marked the sixth consecutive year of sales growth by the top 100 firms, and came even as the global economy shrank. Overall sales were 17 percent higher than in 2015 when it first included data on Chinese firms. “The industry giants were largely shielded by sustained government demand for military goods and services,” Alexandra Marksteiner, researcher with the SIPRI Military Expenditure and Arms Production Programme, said in a statement on Monday. “In much of the world, military spending grew and some governments even accelerated payments to the arms industry in order to mitigate the impact of the Covid-19 crisis.” Firms in the United States continue to dominate the industry, with total sales of $285bn from 41 companies accounting for about 54 percent of all arms sales among the 100 biggest companies. The top five companies in the ranking since 2018 have all been based in the US, SIPRI said. Arms sales from the top Chinese firms amounted to an estimated $66.8bn in 2020, 1.5 percent more than in 2019. Chinese firms accounted for 13 percent of the Top 100 arms sales' total, ahead of the United Kingdom, which had the third-largest share. “In recent years, Chinese arms companies have benefited from the country's military modernization programmes and focus on military-civil fusion,” said Nan Tian, SIPRI senior researcher. “They have become some of the most advanced military technology producers in the world.” The seven UK companies recorded arms sales of $37.5bn in 2020, up by 6.2 percent compared with 2019. Arms sales by BAE Systems – the sole European firm in the top 10 – increased by 6.6 percent to $24bn. (NEXT) You'd Better Watch Out: The Surveillance State Has a Naughty List, and You're On It John W. Whitehead & Nisha Whitehead, December 7, 2021 No longer does the all-knowing, all-seeing, jolly Old St. Nick need to rely on antiquated elves on shelves and other seasonal snitches in order to know when you're sleeping or awake, and if you've been naughty or nice. Thanks to the government's almost limitless powers made possible by a domestic army of techno-tyrants, fusion centers and Peeping Toms, Santa can get real-time reports on who's been good or bad this year. This creepy new era of government/corporate spying—in which we're being listened to, watched, tracked, followed, mapped, bought, sold and targeted—makes the NSA's rudimentary phone and metadata surveillance appear almost antiquated in comparison. Tracking you based on your health status. In the age of COVID-19, digital health passports are gaining traction as gatekeepers of a sort, restricting access to travel, entertainment, etc., based on one's vaccine status. Whether or not one has a vaccine passport, however, individuals may still have to prove themselves “healthy” enough to be part of society. For instance, in the wake of Supreme Court rulings that paved the way for police to use drug-sniffing dogs as “search warrants on leashes,” government agencies are preparing to use virus-detecting canine squads to carry out mass screenings to detect individuals who may have COVID-19. Researchers claim the COVID-sniffing dogs have a 95% success rate of identifying individuals with the virus (except when they're hungry, tired or distracted). These dogs are also being to trained to ferret out individuals suffering from other health ailments such as cancer. Tracking you based on your face: Facial recognition software aims to create a society in which every individual who steps out into public is tracked and recorded as they go about their daily business. Coupled with surveillance cameras that blanket the country, facial recognition technology allows the government and its corporate partners to identify and track someone's movements in real-time. One particularly controversial software program created by Clearview AI has been used by police, the FBI and the Department of Homeland Security to collect photos on social media sitesfor inclusion in a massive facial recognition database. Similarly, biometric software, which relies on one's unique identifiers (fingerprints, irises, voice prints), is becoming the standard for navigating security lines, as well as bypassing digital locks and gaining access to phones, computers, office buildings, etc. In fact, greater numbers of travelers are opting into programs that rely on their biometrics in order to avoid long waits at airport security. Scientists are also developing lasers that can identify and surveil individuals based on their heartbeats, scent and microbiome. Tracking you based on your behavior: Rapid advances in behavioral surveillance are not only making it possible for individuals to be monitored and tracked based on their patterns of movement or behavior, including gait recognition (the way one walks), but have given rise to whole industries that revolve around predicting one's behavior based on data and surveillance patterns and are also shaping the behaviors of whole populations. One smart “anti-riot” surveillance system purports to predict mass riots and unauthorized public events by using artificial intelligence to analyze social media, news sources, surveillance video feeds and public transportation data. Tracking you based on your spending and consumer activities: With every smartphone we buy, every GPS device we install, every Twitter, Facebook, and Google account we open, every frequent buyer card we use for purchases—whether at the grocer's, the yogurt shop, the airlines or the department store—and every credit and debit card we use to pay for our transactions, we're helping Corporate America build a dossier for its government counterparts on who we know, what we think, how we spend our money, and how we spend our time. Consumer surveillance, by which your activities and data in the physical and online realms are tracked and shared with advertisers, has become big business, a $300 billion industry that routinely harvests your data for profit. Corporations such as Target have not only been tracking and assessing the behavior of their customers, particularly their purchasing patterns, for years, but the retailer has also funded major surveillance in cities across the country and developed behavioral surveillance algorithms that can determine whether someone's mannerisms might fit the profile of a thief. Tracking you based on your public activities: Private corporations in conjunction with police agencies throughout the country have created a web of surveillance that encompasses all major cities in order to monitor large groups of people seamlessly, as in the case of protests and rallies. They are also engaging in extensive online surveillance, looking for any hints of “large public events, social unrest, gang communications, and criminally predicated individuals.” Defense contractors have been at the forefront of this lucrative market. Fusion centers, $330 million-a-year, information-sharing hubs for federal, state and law enforcement agencies, monitor and report such “suspicious” behavior as people buying pallets of bottled water, photographing government buildings, and applying for a pilot's license as “suspicious activity.” Tracking you based on your social media activities: Every move you make, especially on social media, is monitored, mined for data, crunched, and tabulated in order to form a picture of who you are, what makes you tick, and how best to control you when and if it becomes necessary to bring you in line. As The Intercept reported, the FBI, CIA, NSA and other government agencies are increasingly investing in and relying on corporate surveillance technologies that can mine constitutionally protected speech on social media platforms such as Facebook, Twitter and Instagram in order to identify potential extremists and predict who might engage in future acts of anti-government behavior. This obsession with social media as a form of surveillance will have some frightening consequences in coming years. As Helen A.S. Popkin, writing for NBC News, observed, “We may very well face a future where algorithms bust people en masse for referencing illegal ‘Game of Thrones' downloads… the new software has the potential to roll, Terminator-style, targeting every social media user with a shameful confession or questionable sense of humor.” Tracking you based on your phone and online activities: Cell phones have become de facto snitches, offering up a steady stream of digital location data on users' movements and travels. Police have used cell-site simulators to carry out mass surveillance of protests without the need for a warrant. Moreover, federal agents can now employ a number of hacking methods in order to gain access to your computer activities and “see” whatever you're seeing on your monitor. Malicious hacking software can also be used to remotely activate cameras and microphones, offering another means of glimpsing into the personal business of a target. Tracking you based on your social network: Not content to merely spy on individuals through their online activity, government agencies are now using surveillance technology to track one's social network, the people you might connect with by phone, text message, email or through social message, in order to ferret out possible criminals. An FBI document obtained by Rolling Stone speaks to the ease with which agents are able to access address book data from Facebook's WhatsApp and Apple's iMessage services from the accounts of targeted individuals and individuals not under investigation who might have a targeted individual within their network. What this creates is a “guilt by association” society in which we are all as guilty as the most culpable person in our address book. Tracking you based on your car: License plate readers are mass surveillance tools that can photograph over 1,800 license tag numbers per minute, take a picture of every passing license tag number and store the tag number and the date, time, and location of the picture in a searchable database, then share the data with law enforcement, fusion centers and private companies to track the movements of persons in their cars. With tens of thousands of these license plate readers now in operation throughout the country, affixed to overpasses, cop cars and throughout business sectors and residential neighborhoods, it allows police to track vehicles and run the plates through law enforcement databases for abducted children, stolen cars, missing people and wanted fugitives. Of course, the technology is not infallible: there have been numerous incidents in which police have mistakenly relied on license plate data to capture out suspects only to end up detaining innocent people at gunpoint. Tracking you based on your mail: Just about every branch of the government—from the Postal Service to the Treasury Department and every agency in between—now has its own surveillance sector, authorized to spy on the American people. For instance, the U.S. Postal Service, which has been photographing the exterior of every piece of paper mail for the past 20 years, is also spying on Americans' texts, emails and social media posts. Headed up by the Postal Service's law enforcement division, the Internet Covert Operations Program (iCOP) is reportedly using facial recognition technology, combined with fake online identities, to ferret out potential troublemakers with “inflammatory” posts. The agency claims the online surveillance, which falls outside its conventional job scope of processing and delivering paper mail, is necessary to help postal workers avoid “potentially volatile situations.” Fusion centers. Smart devices. Behavioral threat assessments. Terror watch lists. Facial recognition. Snitch tip lines. Biometric scanners. Pre-crime. DNA databases. Data mining. Precognitive technology. Contact tracing apps. What these add up to is a world in which, on any given day, the average person is now monitored, surveilled, spied on and tracked in more than 20 different ways by both government and corporate eyes and ears. Big Tech wedded to Big Government has become Big Brother. Every second of every day, the American people are being spied on by a vast network of digital Peeping Toms, electronic eavesdroppers and robotic snoops. In an age of overcriminalization, mass surveillance, and an appalling lack of protections for our privacy rights, we can all be considered guilty of some transgression or other. So you'd better watch out—you'd better not pout—you'd better not cry—‘cos I'm telling you why: this Christmas, it's the Surveillance State that's coming to town, and you're already on its naughty list. (NEXT) Vitamin D: Government Should Have Promoted to Combat Pandemic Joel S. Hirschhorn, December 06, 2021 There seems to be an endless refusal by the public health establishment to fight the pandemic with the best science-based tools.  Instead, they keep pushing vaccines. Great German research provides unequivocal medical evidence that the government should be strongly advocating two actions: 1. Take vitamin D supplements and 2. Have your blood tested for vitamin D. The title for this October 2021 journal article says it all: “COVID-19 Mortality Risk Correlates Inversely with Vitamin D3 Status, and a Mortality Rate Close to Zero Could Theoretically Be Achieved at 50 ng/mL 25(OH)D3: Results of a Systematic Review and Meta-Analysis.”  [25(OH)D3 refers to metabolite of the vitamin in blood] In other words, there is clear evidence that the lower your vitamin D level the greater your risk of dying from COVID infection.  Moreover, the data clearly show that you need a blood level of at least 50 ng/mL. Odds are, however, that very, very few people have been tested for their vitamin D level.  This is a situation where waiting for testing is not the prudent approach.  Vitamin D pills are pretty cheap and it is perfectly safe to take a healthy daily dose to maintain a good immune system.  I take 4,000 IUs twice daily. Here are a number of highlights from this research and other sources; the discussion is aimed at informing people with information not provided by Big Media, Big Government and Big Pharma. Vitamin D is an accurate predictor of COVID infection.  Its deficiency is just as significant, and perhaps more so, than more commonly discussed underlying medical conditions, including obesity. To be clear, there is a level of vitamin D for an effective strategy at the personal and population level to prevent or mitigate new surges and outbreaks of COVID that are related to reduced vaccine effectiveness and new variants. In the German study, fifteen other studies were cited that showed low vitamin D levels were related to cases of severe COVID infection, and seven studies that found positive results from treating ill patients with the vitamin. The German study noted: “The finding that most SARS-CoV-2 patients admitted to hospitals have vitamin D3 blood levels that are too low is unquestioned even by opponents of vitamin D supplementation.” The German study “followed 1,601 hospitalized patients, 784 who had their vitamin D levels measured within a day after admission and 817 whose vitamin D levels were known before infection.  And the researchers also analyzed the long-term average vitamin D3 levels documented for 19 countries.  The observed median vitamin D value over all collected study cohorts was 23.2 ng/mL, which is clearly too low to work effectively against COVID.” Why does this vitamin work so well?  The German study explained: A main cause of a severe reaction from COVID results from a “cytokine storm.” This refers to the body's immune system releasing too many toxic cytokines as part of the inflammatory response to the virus.  Vitamin D is a main regulator of those cells.  A low level of the vitamin means a greater risk for a cytokine storm.  This is especially pertinent for lung problems from COVID. Other studies On a par with the German study was an important US medical article from May 2021: Vitamin D and Its Potential Benefit for the COVID-19 Pandemic.  It noted: “Experimental studies have shown that vitamin D exerts several actions that are thought to be protective against coronavirus disease (COVID-19) infectivity and severity.  … There are a growing number of data connecting COVID-19 infectivity and severity with vitamin D status, suggesting a potential benefit of vitamin D supplementation for primary prevention or as an adjunctive treatment of COVID-19.  … there is no downside to increasing vitamin D intake and having sensible sunlight exposure to maintain serum 25-hydroxyvitamin D at a level of least 30 ng/mL and preferably 40 to 60 ng/mL to minimize the risk of COVID-19 infection and its severity.” This confirms the German study and its finding of a critical vitamin level of 50 ng/mL. Daniel Horowitz has made this correct observation about vitamin D supplementation: “An endless stream of academic research demonstrates that not only would such an approach have worked much better than the vaccines, but rather than coming with sundry known and unknown negative side effects.“ There are now 142 studies vouching for the near-perfect correlation between higher vitamin D levels and better outcomes in COVID patients. From Israel came work that showed 25% of hospitalized COVID patients with vitamin D deficiency died compared to just 3% among those without a deficiency.  And those with a deficiency were 14 times more likely to end up with a severe or critical condition. Also from Israel, data on 1,176 patients with COVID infection admitted to the Galilee Medical Center, 253 had vitamin D levels on record and half were vitamin D-deficient.  This was the conclusion: “Among hospitalized COVID-19 patients, pre-infection deficiency of vitamin D was associated with increased disease severity and mortality.” Several studies have come from the University of Chicago.  One found that a vitamin D deficiency (less than 20 ng/ml) may raise the risk of testing positive for COVID-19, actually a 7.2% chance of testing positive for the virus.  And that more than 80% of patients diagnosed with COVID-19 were vitamin D deficient.  And Black individuals who had levels of 30 to 40 ng/ml had a 2.64 times higher risk of testing positive for COVID-19 than people with levels of 40 ng/ml or greater. On the good news side is a new study from Turkish researchers.  They focused on getting people's levels over 30 ng/mL with supplements.  At that level there was success compared to people without supplementation.  This was true even if they had comorbidities.  They were able to achieve that blood level within two weeks.  Those with no comorbidities and no vitamin D treatment had 1.9-fold increased risk of having hospitalization longer than 8 days compared with cases with both comorbidities and vitamin D treatment. (NEXT) The explosion of Covid PTSD cases is a mental health crisis in the making The Guardian, 7 Dec 2021 When the Covid-19 pandemic began, people working in the trauma field knew the psychological toll would be colossal. In the spring of 2020, I began interviewing professionals about the mental health fallout of the pandemic, specifically its impact on frontline medical staff. During the first wave, two in every five intensive care staff in England reported symptoms of post-traumatic stress disorder. That work continued for almost a year, during which time a second wave hit and the initial traumas were exacerbated. But it wasn't only frontline workers who were experiencing trauma symptoms: Covid has posed perhaps the biggest threat to mental health in England since the second world war. Now, at the tail end of 2021, the pandemic is still not over. The NHS forecasts that nationally, there will be 230,000 new cases of PTSD as a result of Covid-19. It is not only social care and medical staff who will be affected. Those who lost loved ones, and those who have been very ill or hospitalised (35% of Covid-19 patients who were put on a ventilator go on to experience extensive symptoms of PTSD) may also suffer. Then there are those living with the effects of domestic and sexual abuse, which may have worsened due to lockdown, and children and young people whose lives changed immeasurably due to our shift to a state of emergency. I imagine that some women whose birthing experiences were marked by the pandemic will also be experiencing symptoms. The explosion of post-traumatic stress disorder is a medical emergency, and a further strain on our creaking services. Without proper action and investment, it is a national mental health crisis in the making.

Holyoke Media, en asociación con WHMP radio, emiten diariamente la Síntesis informativa en español a través del 101.5 FM y en el 1240 / 1400 AM. Esta es la síntesis informativa del martes 7 de diciembre de 2021: - El presidente Biden, citando el costo "escandalosamente caro" de la insulina y otros medicamentos recetados en los EEUU, pidió al Congreso el lunes que apruebe su proyecto de ley Build Back Better, que contiene disposiciones para reducir los precios de los medicamentos. En breves declaraciones en la Casa Blanca, el presidente señaló el costo de la insulina necesaria para tratar la diabetes tipo 1, que según Biden afecta a unos 1,5 millones de estadounidenses, que pagan entre 375 y 1.000 dólares al mes por el medicamento. La medida aprobada por la Cámara limitaría los precios de la insulina a $ 35 por mes. El plan de Biden también permitiría a Medicare negociar ciertos precios de medicamentos con los fabricantes, algo que ahora está prohibido y limitaría los costos de bolsillo de algunos medicamentos recetados para los beneficiarios de Medicare a $ 2,000 al año. Biden dijo que quiere la aprobación del Congreso de la Ley Build Back Better de aproximadamente 2 billones de dólares "tan pronto como podamos". El líder de la mayoría del Senado, Chuck Schumer, D-N.Y. dijo en una carta del lunes a los senadores que su objetivo es que la medida sea aprobada para Navidad. Ese plazo puede ser difícil de cumplir. El parlamentario del Senado aún está revisando partes del proyecto de ley para verificar el cumplimiento de la llamada regla Byrd, que restringe lo que puede contener la medida. Está previsto que el Senado se vaya de la ciudad para sus vacaciones de Navidad a fines de esta semana, aunque es probable que eso se retrase. Y no está claro qué cambios exigirán algunos demócratas, incluidos Joe Manchin de West Virginia y Kyrsten Sinema de Arizona, su apoyo a la medida, que requerirá los votos de los 50 demócratas del Senado para su aprobación. La industria farmacéutica, que se opone a la Ley Build Back Better, respondió a los comentarios de Biden. En un comunicado, Pharmaceutical Research and Manufacturers of America, dijo que "un proyecto de ley perjudicial bloqueado a través de un proceso partidista no proporcionará a los pacientes que luchan por pagar sus medicamentos un alivio significativo". FUENTE: WBUR, NPR - El Concejo de la Ciudad de Holyoke discutirá y votará este martes en su sesión regular sobre una posible enmienda a la Ordenanza 2-69, en la que se recomendó en la sesión del Comité de Ordenanzas del pasado 23 de noviembre que se adopte la orden y se elimine la sección (g) (2) de la ordenanza. Esa sección establece que "Ningún empleado de la ciudad deberá servir simultáneamente en el concejo de la ciudad durante su tiempo de empleo". Esta ordenanza se hizo con la intención de evitar que los jefes de departamento de la ciudad sean concejales de la ciudad; al mismo tiempo y tal como está escrito, también excluye a cientos de postularse para un cargo. Esto pone a los concejales electos Jenny Rivera e Israel Rivera, en una situación incierta para poder ocupar oficialmente el cargo de concejales. Aunque se perfila una posible votación mayoritaria a su favor, se anticipa que sus oponentes ofrezcan resistencia a permitir que se hagan los cambios necesarios para que los dos concejales electos puedan servir. La sesión ordinaria del concejo comenzará este martes 7 de diciembre a las 7:00 pm y el asunto en cuestión, es el 26a, en una agenda de 56 artículos. FUENTE: HOLYOKE MEDIA

Surely the biggest development in the last year is the record speed with which vaccines were discovered for the Covid-19 virus that shut down the entire world. I spoke to medicinal chemist and science blogger Derek Lowe about the many issues surrounding drug discovery like regulatory constraints, funding, and many other issues in the industry.Enjoy the conversation with Derek Lowe - and the transcript is available for paid subscribers. This is a public episode. Get access to private episodes at www.ideasuntrapped.com/subscribe

Richard Moscicki is the Executive Vice President for Science and Regulatory Advocacy and the Chief Medical Officer at Pharmaceutical Research and Manufacturers of America (PhRMA). Previously he was the Deputy Center Director for Science Operations for the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) and the Chief Medical Officer at Genzyme Corporation. In this podcast, we discuss the U.S. R&D ecosystem and the vital roles that NIH and the private sector play in bringing new therapies to patients. Richard was previously at Massachusetts General Hospital (MGH) and Harvard Medical School, and this strong academic background combined with his industry knowledge gives him a unique perspective on both sides of public and industrial R&D, as well as how NIH developed intellectual property moves from the ‘Eureka' phase to becoming an actual medicine. Our conversation includes President Biden's new $6.5 billion proposal called ARPA-H, modeled on DARPA, specifically for drug discovery, and where those efforts would be best directed to facilitate needed medicines to address unmet medical needs. We also touch on how the rapid evaluation and approval of vaccines for COVID-19 could serve as an improved regulatory blueprint for accelerated evidence driven access to patients.

In this episode, The Mentors Radio host Tom Loarie talks with Steve Ubl, President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) discuss COVID, vaccine development and more.  PhRMA is an organization representing and working with America's leading drug companies. Combined, these companies directly employ more than 854,000 Americans and invest more than $90 billion in research and development every year — more than any other industry in America. Ubl peels back the layers and delivers a first-hand, fascinating, insider look at one of the largest industries in the U.S., including some remarkable new developments. Find Show Notes here and a Podcast of the Radio show below! Sign up for free podcasts of the show here!

R versus SAS - which is a better tool? Today, we talk about a controversial topic. If you go online and look into social media, you'll find a lot of data scientists that talk about R versus Python. In medical and clinical research, it's more about R versus SAS. For this discussion, we have Sam Gardner and Thomas Neitmann representing SAS and R, respectively.

Welcome to Majority.FM's AM QUICKIE! Brought to you by justcoffee.coop TODAY'S HEADLINES: Israeli Prime Minister Benjamin Netanyahu says there is no clear end in sight to the violence in Palestine, as the death toll from Israeli strikes continues to climb despite widespread international calls for a ceasefire. Meanwhile, the GOP has a new target in their war on voting rights: poll workers. They’re seeking to levy harsh penalties for anyone who makes a mistake while working on an election. And finally, the Intercept reports that Big Pharma is doing all it can to lobby lawmakers toward stopping Joe Biden’s support for worldwide access to generic COVID vaccines. THESE ARE THE STORIES YOU NEED TO KNOW: Israeli forces killed dozens more Palestinians over the weekend and destroyed the building housing both the Associated Press and Al Jazeera’s offices in the Gaza strip in an airstrike, and Israeli Prime Minister Benjamin Netanyahu says there is no end in sight to the violence. Palestinian authorities say Israeli strikes have killed at least 192 people, including 58 children. Rocket attacks launched from Gaza have killed at least 10 people in Israel. Those numbers show just the tip of the iceberg of violence unleashed on the Gaza strip in the past week. Israeli forces have destroyed apartment buildings, damaged medical facilities, and leveled family homes, all under the familiar auspices of “fighting terror.” That was their excuse yet again when on Saturday, airstrikes destroyed the building that housed both the Associated Press and Al Jazeera offices in Gaza. Israeli officials claimed that Hamas forces were also using the structure, and warned journalists to evacuate before leveling the building. Yet Netanyahu gave no clear evidence that Hamas was in the area. Meanwhile, international calls for a cease-fire are mounting. The Times reports that Biden spoke to both Netanyahu and Palestinian Authority president Mahmoud Abbas in an attempt to broker a ceasefire, but to no avail. The U.N. Security Council met to discuss the issue, but took no concrete action. And all the while, the people of Palestine continue to suffer. GOP Takes Aim at Poll Workers The New York Times has a new story out about a disturbing aspect of the GOP’s push to kill democracy. New laws in Texas and several other states would specifically target poll workers and election officials, making any small mistake punishable by extreme fines and even in some cases jail time. The Times reports that poll workers say they’ve experienced a severe uptick in harassment by poll watchers and other partisan agents in recent elections. In addition to that, new voting laws across the country have started to crack down on these workers, as well as nonpartisan election officials. The Times reports that various laws are leveling the threat of felonies, jail time and fines as large as $25,000 over the heads of election officials who make innocent mistakes in the process. All of this is a direct result of the GOP’s embrace of election conspiracies and Donald Trump’s continued insistence that he won the 2020 election, of course. Listen to this quote from Chris Davis, the county election administrator in Williamson County, Texas: “These poll workers don’t ever, in our experience, intend to count invalid votes, or let somebody who’s not eligible vote, or prevent somebody who’s eligible from voting. Yet we’re seeing that as a baseline, kind of a fundamental principle in some of the bills that are being drafted. And I don’t know where it’s coming from, because it’s not based on reality.” Poll workers work extremely long hours for very little pay, often out of a sense of duty. But experts think these draconian penalties will start to scare some of the most experienced among them away. That’s bad for democracy -- or in other words, good for the GOP. Big Pharma Lobbies Congress to Stop Patent Waivers The Intercept reports that Big Pharma is up to its usual tricks: lobbying behind the scenes to make the world a more miserable place. Last week, the U.S. announced that it would support the World Trade Organizations’ proposal to temporarily waive enforcement of the patents on COVID vaccines, which would allow many struggling nations to develop their own generic vaccines and get them to their citizens without paying an arm and a leg to U.S. companies. According to new documents the Intercept obtained, Pharma lobbyists have been goading a core group of House Republicans into opposing this effort at all costs. Many lobbyists in question work for the Pharmaceutical Research and Manufacturers of America, a trade group that represents Pfizer, Johnson & Johnson, AstraZeneca and other big firms -- in other words, exactly the people who will profit from keeping a tight lock on the patents. Their effort was enough to convince 29 House Republicans to sign on to an as-yet-unsent letter to Biden urging him to roll back his support for the WTO plan. The letter leans into the lobbyists talking points, also obtained by the Intercept, which claim that the waiver would cost American jobs and allow China to “profit from our innovation.” The play they’re making is simple: try to use Chinese and Russian fearmongering to get Biden to back down. With any luck, the President is going to see right through that -- but who knows how many corporate Democrats might be susceptible to the same kind of crap. One to keep an eye on, for sure. AND NOW FOR SOME QUICKER QUICKIES: Neera Tanden finally made her way into the White House, after her humiliating failure to gain an actual confirmed seat at the OMB because of her awful Twitter feed, she will be joining the Biden Administration as a senior advisor. My guess is she probably won’t be giving social media advice! The Military Times reports that U.S. Space Force Lt. Colonel Matthew Lohmeier [LOW MEYER] was dismissed from his post after he went on a podcast to promote his new self-published book, titled “Irresistible Revolution: Marxism's Goal of Conquest & the Unmaking of the American Military." Sounds like the Space Force isn’t attracting America’s finest. There’s a new George Bush on the scene! Yep, you heard that right. George P. Bush, the large adult son of one Jeb Bush, is considering a run for Texas Attorney General. We will never be free from this family at this rate! The messy Matt Gaetz cycle continues. A new report by the Daily Beast alleges that Gaetz’s associates gave a kushy county government contract to an influencer, model, and escort that Gaetz frequently partied with, allowing her to collect thousands of dollars in taxpayer money for doing, well, not a whole lot. AM QUICKIE - MAY 17, 2021 HOSTS - Sam Seder & Lucie Steiner WRITER - Jack Crosbie PRODUCER - Dorsey Shaw EXECUTIVE PRODUCER - Brendan Finn

QUESTION PRESENTED:Whether a defendant in a patent infringement action who assigned the patent, or is in privity with an assignor of the patent, may have a defense of invalidity heard on the merits.DateProceedings and Orders (key to color coding)Sep 30 2020 | Petition for a writ of certiorari filed. (Response due November 5, 2020)Oct 14 2020 | Blanket Consent filed by Petitioner, Minerva Surgical, Inc.Nov 05 2020 | Brief of respondents Hologic, Inc., et al. in opposition filed.Nov 05 2020 | Brief amici curiae of Intellectual Property Professors filed.Nov 05 2020 | Brief amicus curiae of Engine Advocacy filed.Nov 24 2020 | DISTRIBUTED for Conference of 12/11/2020.Nov 24 2020 | Rescheduled.Nov 24 2020 | Reply of petitioner Minerva Surgical, Inc. filed.Dec 09 2020 | DISTRIBUTED for Conference of 1/8/2021.Jan 08 2021 | Petition GRANTED.Feb 22 2021 | Brief of petitioner Minerva Surgical, Inc. filed.Feb 22 2021 | Joint appendix volumes 1 and 2 with supplemental appendix filed. (Statement of costs filed)Feb 22 2021 | Blanket Consent filed by Petitioner, Minerva Surgical, Inc.Feb 25 2021 | Brief amicus curiae of New York Intellectual Property Law Association in support of neither party filed.Feb 26 2021 | Brief amicus curiae of Engine Advocacy filed.Mar 01 2021 | Brief amici curiae of Intellectual Property Law Professors filed.Mar 01 2021 | Brief amicus curiae of Intellectual Property Owners Association filed in support of neither party.Mar 01 2021 | Brief amicus curiae of American Intellectual Property Law Association filed in support of neither party.Mar 01 2021 | Brief amicus curiae of United States in support of neither party filed.Mar 01 2021 | Brief amicus curiae of New York City Bar Association in support of neither party filed.Mar 12 2021 | SET FOR ARGUMENT on Wednesday, April 21, 2021.Mar 15 2021 | Record requested.Mar 24 2021 | Brief of respondents Hologic, Inc., et al. filed.Mar 26 2021 | Motion of the Acting Solicitor General for leave to participate in oral argument as amicus curiae and for divided argument filed.Mar 30 2021 | CIRCULATEDMar 31 2021 | Brief amicus curiae of United Therapeutics Corp. filed. (Distributed)Mar 31 2021 | Brief amicus curiae of Pharmaceutical Research and Manufacturers of America filed. (Distributed)Mar 31 2021 | Brief amici curiae of Leading Technology Composites, Inc. and Clarkwestern Dietrich Building Systems LLC filed. (Distributed)Apr 05 2021 | Motion of the Acting Solicitor General for leave to participate in oral argument as amicus curiae and for divided argument GRANTED.Apr 07 2021 | Reply of petitioner Minerva Surgical, Inc. filed. (Distributed)Apr 21 2021 | Argued. For petitioner: Robert N. Hochman, Chicago, Ill. For United States, as amicus curiae: Morgan L. Ratner, Assistant to the Solicitor General, Department of Justice, Washington, D. C. For respondents: Matthew M. Wolf, Washington, D. C.★ Support this podcast on Patreon ★

Stephen Ubl is the president and CEO of the Pharmaceutical Research and Manufacturers of America, known as PhRMA, which represents America's leading biopharmaceutical research companies.  The U.S. biopharmaceutical sector directly employs more than 800,000 Americans and invests more than $100 billion in research and development annually -- more than any other industry in America.  Steve leads the advocacy for this industry in Washington, DC and across the country.  A policy expert with a record of enacting meaningful healthcare reform, Steve joins me today to do a deep dive on the drug industry – examining costs, the supply chain, and the industry's unprecedented response to Covid-19.

On this episode of .think Atlantic, IRI's Thibault Muzergues is joined by Katalin Cseh, Mohand Sidi-Said, and IRI's Zuzana Palušáková. The discussion centers around a new report by the International Republican Institute (IRI), in partnership with the Alliance for Liberals and Democrats in Europe (ALDE) and the European Liberal Forum (ELF), which measures European sentiment on COVID-19 and its fallout across the region. What are the main takeaways from the data? How are Europe and North America going to exit the health crisis in the coming months? How can we improve our health systems to make them more resilient? How do we ensure that the governments will give back all the public freedoms they took away during the pandemic? Thibault Muzergues and his guests debate all these questions - and many more. Katalin Cseh is a Hungarian Member of the European Parliament, and vice-chair of the Renew Europe parliamentary group - she hails from the Hungarian liberal party Momentum. She is also a member of the Committee on Industry, Research, and Energy and is part of the delegation for relations with the United States. Mohand Sidi-Said is a Franco-Algerian philanthropist, former Vice-President of Pfizer, and of the Pharmaceutical Research and Manufacturers of America, which represents the Pharmaceutical industry in the United States. Find Katalin on Twitter at @katka_cseh Find Mohand on Twitter at @MohandSidi. Find Thibault on Twitter at @tmuzergues Visit IRI’s website at www.iri.org Further reading: European public opinion perception about Covid-19 report (https://www.iri.org/sites/default/files/iri_european_public_opinion_perception_about_covid-19_final_version_.pdf)

This is Derek Miller Speaking on Business. The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Here is a message about the COVID-19 vaccine from PhRMA. KELLY MCALEER In these unprecedented times, America's biopharmaceutical companies are making great progress against COVID nineteen. Clinical trials are taking place all over the country, including right here in Utah. The recent news on vaccines and treatments are highlighting the incredible progress being made - and bringing hope. From development to clinical trials, and throughout the manufacturing process - these medicines and vaccines are rigorously tested for safety, effectiveness, and quality. Until vaccines are available to all Utahans, please continue doing your part to stay safe by social distancing, wearing a mask and washing your hands. Because following the science is how we get back to normal. DEREK MILLER We are grateful for the vital and unprecedented work being done by the companies represented by PhRMA and will continue to encourage all to do their part while we await the arrival of the vaccines. For updates on how the biopharmaceutical industry is working to defeat COVID-19, visit Phrma.org/coronavirus. I'm Derek Miller, with the Salt Lake Chamber, and this is Speaking on Business. Originally aired: January 8, 2021.

Super excited and honored for today's episode with special guest, Autumn Schulze. Autumn is a Bio-Medical Scientist, Herbal Medicine Practitioner, Holistic Gut, Health Coach, and Food as Medicine expert. She crushes the game when it comes to natural holistic alternatives to medicine. ( Hell, she once helped make and do pharmaceutical trails) Her story is inspiring and you don't want to miss out! In today's episode, we'll be learning about: ·      DIS-EASE: Figuring out what's going on in your body, evey symptom has a meaning. ·      WE ARE ANIMALS: Remembering that we are animals and we have feelings and emotions and giving ourselves the space to process how we feel. ·      ADAPTOGENS: Help the body adapt to stress like ashwagandha ·      ADMITTING: You must admit you are doing things that hurt yourself. That's the first step toward longer term change. ·      STRAIGHT LINE: Healing isn't a liner/ straight line. You'll have good days and bad days. ·      PIVOT: Pivoting and allowing yourself to see the lessons along the way is the magic for sustainable change. About the Guest: Autumn Schulze is a Bio-Medical Scientist, Herbal Medicine Practitioner, Holistic Gut Health Coach & Food as Medicine expert. Autumn had spent 13 years in Pharmaceutical Research before her Father's Cancer returned. She decided to educate herself on healing naturally to help her Father and also ended up helping herself heal. Since then Autumn supports, guides & empowers others to heal their gut, reverse fatigue all while learning to love to live in their bodies again. She does this via her signature ‘Thyme to Thrive' health education program & ‘Harvest Your Health' method. Video is her preferred medium of expression so she has created a number of online courses in addition to offering seasonal Herbal Apothecary Products. Autumn lives outside of Austin, Texas with her Wife Beth, 4 Pomeranians and 1 Orange Tabby. She loves reading, learning & getting lost in gardening. She enjoys to travel with her RV. Find Autumn on Social Media: Website:https://www.autumnsharvest.tv/?fbclid=IwAR16FSbxZ5vDLs-AHi1e3kCweVG8OWM4arA0a7D1ClyML1R_6ll8ziTg2RQ ( https://www.autumnsharvest.tv/) Health & Body Sisterhood Facebook Group:https://www.facebook.com/groups/1509077392633599/ ( https://www.facebook.com/groups/1509077392633599/) Facebook Business Page:https://www.facebook.com/AutumnsHarvest.TV/ ( https://www.facebook.com/AutumnsHarvest.TV/) YouTube:https://l.facebook.com/l.php?u=https%3A%2F%2Fwww.youtube.com%2Fchannel%2FAutumn%27sHarvest%3Ffbclid%3DIwAR1gXJSh8FO_1rNkA0-cK76zwLY47z0Espsbpw1asxFNIZ2Y7576xXwdbcU&h=AT2U9I8vnPcUkJ52b1HxyipHpyqT6llGt6I-YvGk5uJXceUBszx3wdmZNj-3Bjs1xZ2lgqR_84_DJILLEH55dssIvnfM8uF6WWSrLa36lSBZT9exw8lTdKGLuFkgAJWg81qktwYJ ( https://www.youtube.com/channel/Autumn'sHarvest) Instagram:https://www.instagram.com/Autumns_Harvest/?fbclid=IwAR1nY9KK_D8FledisqRb8Vl8KmN6BwEIBNdRBF1m26FttLkM2HdyIB3XEtQ ( )https://www.instagram.com/Autumns_Harvest (https://www.instagram.com/Autumns_Harvest)   About the Host: Melanie is uberly passionate about all things mindset, nutrition, and wellness. She's been deep diving into the wellness industry for over six years. She's learned to master her craft while working with others to get to the root cause of what's holding them back from their goals and bigger vision. Melanie currently lives in Austin, Texas, with her husband, Oliver, and her son, Elliott. She enjoys being in nature, taking care of her house plants, reading, and snuggles with her boys. Find Plant Ahead on Social Media: Instagram: http://www.instagram.com/plantahead.co (www.instagram.com/plantahead.co) Facebook: http://www.facebook.com/melanie.petrilli (www.facebook.com/melanie.petrilli) Twitter:...

Welcome back to today's Friday Review where I'll be breaking down the best of the week! I'll be sharing specifics on these topics: Happy New Year! Community Detox New Years Books and Journals Oil Pulling (product review) Virus and Pharmaceuticals (research) Fertility Testing for Men (research) For all the details tune into today's Cabral Concept 1792 – Enjoy the show and let me know what you thought! - - -   Show Notes & Resources: http://StephenCabral.com/1792 - - - Dr. Cabral's New Book, The Rain Barrel Effect https://amzn.to/2H0W7Ge - - - Join the Community & Get Your Questions Answered: http://CabralSupportGroup.com - - -  Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Stress, Sleep & Hormones Test (Run your adrenal & hormone levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels)

Welcome back to today's Friday Review where I'll be breaking down the best of the week!   I'll be sharing specifics on these topics: Happy New Year! Community Detox New Years Books and Journals Oil Pulling (product review) Virus and Pharmaceuticals (research) Fertility Testing for Men (research) For all the details tune into today's Cabral Concept 1792 - Enjoy the show and let me know what you thought! - - -   Show Notes & Resources: http://StephenCabral.com/1792 - - - Dr. Cabral's New Book, The Rain Barrel Effect https://amzn.to/2H0W7Ge - - - Join the Community & Get Your Questions Answered: http://CabralSupportGroup.com - - -  Dr. Cabral’s Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Stress, Sleep & Hormones Test (Run your adrenal & hormone levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels)

We discussed a number of things including: 1. The battle against COVID and the progress on vaccines and treatments 2. The state of innovation in biotech and pharma industries 3. Forecasts for healthcare in 2021 and beyond Fred is a Director with the private equity firm, Warburg Pincus. He is also a Board member of Amgen, Intrexon, Modernizing Medicine, Theramex and Vertice. Fred is the former Chairman of the Board and Chief Executive Officer of Schering-Plough Corporation. Prior to joining Schering-Plough in April 2003, he was Chairman and Chief Executive Officer of Pharmacia Corporation – a company that was formed in March 2000 as a result of the merger of Monsanto and Pharmacia and Upjohn. Hassan joined Pharmacia & Upjohn as Chief Executive Officer in 1997. Previously, Hassan was Executive Vice President of Wyeth, with responsibility for its pharmaceutical and medical products business. He was elected to Wyeth's Board of Directors in 1995. Earlier in his career, Hassan spent 17 years with Sandoz Pharmaceuticals (now Novartis) and headed its U.S. pharmaceuticals business. Hassan received a B.S. degree in chemical engineering from the Imperial College of Science and Technology at the University of London and an M.B.A. from Harvard Business School. Hassan has chaired significant pharmaceutical industry organizations including The Pharmaceutical Research and Manufacturers of America (PhRMA) and The International Federation of Pharmaceutical Manufacturers Associations (IFPMA). Fred's book, "Reinvent - A Leader's Playbook for Serial Success," was published in 2013 by Wiley and has been discussed in many global organizations including the World Bank. In 2014, a CNBC panel named Hassan to a list of those who have had the most profound impact on the world of business in the previous quarter century.

Latest reports indicate that COVID-19 cases are on the rise throughout the U.S., and many warn of more difficult days to come with the onset of winter. Throughout the pandemic, leaders have indicated that getting the pandemic under control hinges on creating and distributing a vaccine. But now that the first of the vaccines are rolling out to the public, consumers want answers to several pressing questions: how were these vaccines developed so fast? Will they be available for everybody? How will they distribute them? Most importantly, are they safe?In this Fight Back! episode, we talk with vaccine expert Dr. Mike Ybarra, an Emergency Room Physician, and Vice President of Medical Affairs and Strategic Alliances at the Pharmaceutical Research and Manufacturers Association. Dr. Ybarra has over ten years of advocacy, health policy, and direct patient care experience. His background and knowledge will help us take a deep dive into the development of the COVID vaccine, its technology, and its implications for the public.

Michael Patterson is the CEO of US Cannabis Pharmaceutical Research and Development LLC (US Cannabis), a privately-held developmental consulting firm that was established in 2014 with the mission of moving society forward through legalized cannabis. US Cannabis develops the legal cannabis/hemp/CBD markets globally across all platforms (education, cultivation, production, dispensing, research and development, management operations and compliance, and physician services). US Cannabis currently works with national, state, and local governments, sovereign nations, and public/private companies in all aspects of the cannabis/hemp/CBD industry throughout the United States and Internationally. Mr. Patterson is a board member of MGMC-Pharma, an international medical cannabis pharmaceutical corporation with cannabis cultivation, production, and export/distribution licenses in 5 East African Countries (Lesotho, Tanzania, Malawi, Democratic Republic of Congo, Uganda).Mr. Patterson is also a board member for the Medical Cannabis Society, Tourette’s Syndrome Awareness Foundation, Cannabis/Hemp/CBD industry writer for Florida MD Magazine, Orlando Medical News, and licensed Occupational Therapist and Nursing Home Administrator in 4 states: NJ, NC, VA, FL).

Olga and Natallia discuss their new book Quantitative Methods in Pharmaceutical Research and Development: Concepts and Applications.

In this episode, The Mentors Radio host Tom Loarie talks with Steve Ubl, President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) discuss COVID, drug development and his career.  PhRMA represents America's leading drug companies. These companies directly employ more than 854,000 Americans and invest more than $90 billion in research and development every year -- more than any other industry in America. Ubl peels back the layers and delivers a first-hand, fascinating, insider look at one of the largest industries in the U.S., including some remarkable new developments. Find Show Notes here and a Podcast of the Radio show below! Sign up for free podcasts of the show here! NOTE: This Podcast episode contains extra segment not aired!

In today's episode of 'This House Debates', Heather sits down with Isaac and Sarah (Side Proposition) and Emily and Ivy (Side Opposition) to explore the topic 'This House Would Nationalize Pharmaceutical Research'. Together the four debaters discussed the impacts of price gouging in the industry, effectiveness of government control, and the applications of free market in medicine.Please note: the debaters were assigned a side of the debate by the THW Debate Podcast Team. The views, ideas, and examples presented by the debaters do not represent nor reflect their own.Enjoy the episode! Email us at thwdebatepodcast@gmail.com for feedback, topics you would like to see in future episodes, and/or opportunities to work together.Credits:Producer: Heather YuanHost: Heather YuanEditor: Eric JiangCover Art: @onlyooh_Follow us on instagram and Facebook @thwdebatepodcast

The pandemic has put a lot of pressure on both our health care system and the scientific process — exposing weaknesses that have long existed, but only now become impossible to ignore. On this episode, we take a look at some of the hard truths that COVID-19 is revealing, and what can be done about them. We hear stories about America’s problem with drug shortages, how COVID-19 is affecting the lives of young doctors, and the devastating reality of racial health disparities in New Orleans. Also heard on this week’s episode: President Donald Trump promoted hydroxychloroquine as a potential COVID-19 treatment in March, causing a surge in demand, and shortages for patients who needed it. But even before the pandemic, drug shortages have led to missed cancer treatments, and even deaths. Reporter Alan Yu talks with Rebecca Mosner, Ethan Daniels, Chip Davis from the Healthcare Distribution Alliance, Ryan Marable from Kroger and the National Pharmaceutical Association, Erin Fox from University of Utah Health, Rena Conti from the Boston University Questrom School of Business, Anne Pritchett from the Pharmaceutical Research and Manufacturers of America. Racial health disparities exist across the country — but in New Orleans, recently, ProPublica has found they led to the deaths of elderly Black patients who were sent home to die after contracting COVID-19. We talk with the investigative reporters behind that story, Annie Waldman and Joshua Kaplan. NYU medical ethicist Art Caplan talks about the importance of a slow and deliberate process in scientific research, even when the pressure for breakthroughs is great.

This article was originally published by Mahendra Saini, Nikhita Parihar, Shankar Lal Soni, and Vandana Sharma in the Asian Journal of Pharmaceutical Research and Development. 2020; 8(4): 194-212 under an… The post Drug Repurposing: An Overview  appeared first on DrugPatentWatch - Make Better Decisions.

COVID-19 has heavily impacted communities of color, making health inequities even worse. This BrainStorm webcast is the second in a series on health equity challenges created by COVID-19 in the dementia community and beyond. Our host, Meryl Comer, talks with an expert panel of research organizations about what they are doing to prioritize health equity in their COVID-19 research programs and why diversity matters in brain health research. We also share our latest A-LIST survey results on the pandemic's effects on the Alzheimer's community. Our guests include Gerren Wilson of Genentech; Phyllis Ferrell of Eli Lilly; Dr. Jaime Perales of Kansas University’s Alzheimer’s Disease Center; Kevin Kimble of the Southern Christian Leadership Conference; and Jason Resendez of our LatinosAgainstAlzheimer’s Coalition. We also talk one-on-one with caregiver-advocate Daisy Duarte and former U.S. Surgeon General Dr. David Satcher.Support the show (https://www.usagainstalzheimers.org/ways-donate)

In this episode of The Workplace podcast, CalChamber President and CEO Allan Zaremberg, and Pharmaceutical Research and Manufacturers of America (PhRMA) Chief Medical Officer and Executive Vice President of Science and Regulatory Advocacy Richard Moscicki, M.D., discuss how increased testing, medical treatments and vaccines can provide short- ,middle- and long-term solutions to battling the COVID-19 pandemic crisis and reopening the economy.

Robert Zirkelbach is the Executive Vice President of Public Affairs for the Pharmaceutical Research and Manufacturers of America (PhRMA) – the trade association representing the country’s leading biopharmaceutical research companies. Prior to joining PhRMA, Zirkelbach was Vice President of Strategic Communications at America’s Health Insurance Plans (AHIP). Previously, Zirkelbach was Press Secretary for Congressman Jim Nussle (R-IA) where he served as a spokesman for the Congressman and helped craft public messaging on all Congressional-related matters. TOPIC... America’s pharmaceutical industry working defeat COVID-19!! Dr. Gerard Lameiro is an author, philosopher, economist, and engineer. He is the author of five books and is a popular TV and Talk Radio show guest. Dr. Lameiro was a member of the 1980 Presidential Electoral College and personally cast one electoral vote for Ronald Reagan for President of the United States of America. Dr. Lameiro accurately predicted a Trump victory long before most pollsters and pundits gave Trump even a small chance of winning the presidential election. Dr. Lameiro correctly predicted every State that candidate Trump actually carried in the 2016 election. He has written six books — his latest book is entitled, “Real World Socialism” TOPIC...When we can get back on our economic feet!! Rick Manning is a Conservative Commandoes alumnus. He is also the President of Americans for Limited Government. Rick is a thought leader and strategic thinker which is one of the reasons he served on President Trump’s transition team. He is also the author of the new book with Starr Parker — "Necessary Noise: How Donald Trump Inflames the Culture War and Why this is good for America!” TOPIC...Liberals in Washington must stop opposing America!!

This week we're joined by the incredibly passionate Michael Patterson, cannabis expert and CEO at US Cannabis Pharmaceutical Research and Development. Together, we discuss Michael's worldwide business operations, why big cannabis want a piece of the market in Europe, and the ways in which Covid-19 has affected the cannabis market.Episode SummaryBy training, Michael is a healthcare executive and occupational therapist and has a wealth of experience in the industry, including running a nursing home group worth $230m. In 2014, Michael connected with a war veteran, Saul who had been using opiates for chronic back pain sustained in service. At the time, he was withdrawing from opiates and was interested in using medical cannabis for his pain. This encounter inspired Michael to take action, and so he entered the cannabis industry to help other people like Saul.In 2014, Michael founded US Cannabis Pharmaceutical Research and Development. The company is focused on moving society forward through legalized Cannabis and Hemp. They consult, collaborate, and partner in all aspects of the industry including, but not limited to, investment analysis, R&D, operations and compliance management, international transport and trade, laws-regulation, technology (blockchain, crypto), licensing, banking, cultivation/processing/dispensing, and economic development. The company currently have 5 medical cannabis licenses in Africa (Tanzania, Democratic Republic of Congo, Uganda, Zimbabwe, and Lesotho) and one in Portugal. They also import and export cannabis products into and out of Europe, and are contracted to grow cannabis for THC in Africa.Michael founded US Cannabis Pharmaceutical Research and Development are also working with companies across the world within the areas of software, blockchain, and cryptocurrency.THC is considered an ‘API' or an Active Pharmaceutical Ingredient, which is then sold to pharmaceutical companies to process and make medicine from. In the USA, the average proportion of a state who qualify for medical cannabis is 2-5%.Big Cannabis is interested in the European market as medicine in this part of the world tends to me more socialised and the government tends to pay for medicines. The population of Europe is much larger than the USA, so many of the big players from North America are hoping to gain market share in the EU as the market develops.CBD processing plants in the US are diversifying as there is a trend towards growing hemp for fibre and industrial uses.In the USA, access to cannabis is considered essential during Covid-19, which legitimises it as a medicine.93% of Americans want medical cannabis legalised, and 65% want recreational cannabis legal. Many of the states in the USA who did not previously allow home delivery have now been forced to due to the pandemic. Sales of flower and edibles have also risen during this time.Michael believes that public safety, patient access and commerce all need to work together in harmony for the system to become/remain successful. QuotablesMoving into 2021, you're going to start to see a bigger interest from pharmaceutical companies who want to get more involved [with cannabis] 13:38The EU is where to be. Everybody wants to be there. 14:20Covid-19 will legitimise cannabis as a medicine 31:10ResourcesJoin Michael on LinkedIn: https://www.linkedin.com/in/michael-patterson-nha-otr-l-ceas-88485051/USCPRD Website: http://www.uscprd.com/

Bibliography Campbell, K. (2007, July 26). Your guide to the difference between fermented foods and probiotics. Retrieved from : Gut Microbiota for Health: https://www.gutmicrobiotaforhealth.com/en/guide-difference-fermented-foods-probiotics/ Ferdousi, R., Rhoumi, M., … Homayouni, R.A. (2013). Evaluation of Probiotic Survivability in Yogurt Exposed To Cold Chain Interruption. Iranian Journal of Pharmaceutical Research, 139–44. Hasan, N. & Yang, H. (2019). Factors affecting the composition of the gut microbiota, and its modulation.” PeerJ. Hodges, R. (2019, November 12). When Do Fermented Foods Outperform Probiotic Supplements? Retrieved from Doctor Kara Fitzgerald Functional Medicine: https://www.drkarafitzgerald.com/2018/09/26/when-do-cultured-foods-outperform-probiotic-supplements/. Tetel, M. J., de Vareis, G.J.,... O'Mahony, S.M. 2018). Steroids, stress and the gut microbiome-brain axis. Journal of neuroendocrinology. Kechagia, M., Basoulis, D., …Fakiri, E.M. (2013). Health benefits of probiotics: a review. ISRN nutrition Khalesi, S., Bellissimo, N., Vandelanotte, C., … Irwin, C. (2019). A Review of Probiotic Supplementation in Healthy Adults: Helpful or Hype?. European Journal of Clinical Nutrition. 24–37. Kolaček, S., Hojsak, I., Berni Canani, R.,... Wizman, Z. (2017). Commercial Probiotic Products: A Call for Improved Quality Control. A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics. Journal of Pediatric Gastroenterology and Nutrition.117–24. Lamoureux, V. (2017). Factors affecting the gut microbiome. Dalhousie University. Langdon, A., Cook, N. & Dantas, G. (2016, April 13). The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome medicine. Meybodi, N.M, Mortazavian, A., Sohrabvandi, S., Gomes da Cruz, A. & Mohammadi, R. (2017). Probiotic Supplements and Food Products: Comparison for Different Targets. Official Journal of National Nutrition and Food Technology Research Institute. Rothschild, D., Weissbrod, O., ... Segal, E. (2018).Environment dominates over host genetics in shaping human gut microbiota. Nature 555. 210–215. Swanson, L. (2013). How To Read a Probiotic Label Like an Expert and Get The Best Probiotic Possible.Retrieved from: Probiotics 101: http://probiotics101.probacto.com/how-to-read-a-probiotic-label-like-an-expert-and-get-the-best-probiotic-possible/ Scudellari, M. (2017, February 14). News Feature: Cleaning Up the Hygiene Hypothesis. PNAS.1433-1436. Tun, H.M., Konya, T. & Takaro, T.K. (2017). Exposure to household furry pets influences the gut microbiota of infants at 3–4 months following various birth scenarios. Microbiome. Zheng, M., Zhang, R., Tian X., Zhou, X., Pan, X. & Wong, A. (2017, May 19). Assessing the Risk of Probiotic Dietary Supplements in the Context of Antibiotic Resistance. Frontiers in Microbiology. Wen, L. & Andrew D. (2017). Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes. The Journal of nutrition.